##### Table of Contents



---

---

SECURITIES AND EXCHANGE
COMMISSION

WASHINGTON, DC 20549


FORM 10-Q

(Mark One)

| | [ X ]                                         |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
| | --------------------------------------------- |  | ---------------------------------------------------
| | THE SECURITIES
EXCHANGE ACT OF 1934.         
|
| | For the quarterly period ended
March 31, 2003

OR

| |                                                   |  |                                                                                          
| | ------------------------------------------------- |  | -----------------------------------------------------------------------------------------
| | [   ]                                             |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.
|
| | For the transition period from
       to
       .

Commission File No. 0-18734

AVANIR PHARMACEUTICALS

(Exact name of registrant as specified in its charter)


|                                                                          |  |                                                
|------------------------------------------------------------------------- |  | -----------------------------------------------
|California
(State or other jurisdiction of
incorporation or organization) |  | 33-0314804
(I.R.S. Employer Identification No.)

|                                                                                                      |  |                  |  | 
|----------------------------------------------------------------------------------------------------- |  | ---------------- |  | 
|11388 Sorrento Valley Road, Suite 200, San Diego, California
(Address of principal executive offices) |  | 92121
(Zip Code)
|                                                                                                      |  |                  |  | 
|(858) 622-5200
(Registrants telephone number, including area code)                                  

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter periods that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. YES [X] NO [   ]

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). YES [   ] NO [X]

The number of shares of Common Stock of the registrant issued and outstanding
as of May 1, 2003:

| |                                    |  |            |  |  | 
| | ---------------------------------- |  | ---------- |  |  | 
| | Class A Common stock, no par value |  | 58,427,733 | 
| | Class B Common stock, no par value |  | 13,500     | 
| |                                    |  |            |  |  | 



---

---





---

TABLE OF CONTENTS



|                              |                                                                                               |                                            |  |  |  |  |  | 
|----------------------------- | --------------------------------------------------------------------------------------------- | ------------------------------------------ |  |  |  |  |  | 
|PART I. FINANCIAL INFORMATION
|                              | Item 1. FINANCIAL STATEMENTS                                                                 
|                              |                                                                                               | INDEPENDENT ACCOUNTANTS REPORT           
|                              |                                                                                               | CONSOLIDATED BALANCE SHEETS               
|                              |                                                                                               | CONSOLIDATED STATEMENTS OF OPERATIONS     
|                              |                                                                                               | CONSOLIDATED STATEMENTS OF CASH FLOWS     
|                              |                                                                                               | NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|                              | Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|                              | Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                           
|                              | Item 4. CONTROLS AND PROCEDURES                                                              
|PART II. OTHER INFORMATION   
|                              | Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS                                  
|                              | Item 6. EXHIBITS AND REPORTS ON FORM 8-K                                                     
|SIGNATURES                   
|EXHIBIT INDEX                
|EXHIBIT 10.1                 
|EXHIBIT 10.2                 
|EXHIBIT 10.3                 
|EXHIBIT 10.4                 
|EXHIBIT 10.5                 
|EXHIBIT 10.6                 
|EXHIBIT 15.0                 
|EXHIBIT 99.1                 
|EXHIBIT 99.2                 



---



##### Table of Contents



Table of Contents

|         |  |                                                                                       |  |     
|-------- |  | ------------------------------------------------------------------------------------- |  | ----
|         |  |                                                                                       |  | Page
|         |  |                                                                                       |  |     
|PART I.  |  | FINANCIAL INFORMATION                                                                 |  |     
|Item 1.  |  | Financial Statements                                                                  |  |     
|         |  | Independent Accountants Report                                                       |  | 3   
|         |  | Consolidated Balance Sheets                                                           |  | 4   
|         |  | Consolidated Statements of Operations                                                 |  | 5   
|         |  | Consolidated Statements of Cash Flows                                                 |  | 6   
|         |  | Notes to Consolidated Financial Statements                                            |  | 7   
|Item 2.  |  | Managements Discussion and Analysis of Financial Condition
and Results of Operations |  | 16  
|Item 3.  |  | Quantitative and Qualitative Disclosures about Market Risk                            |  | 34  
|Item 4.  |  | Controls and Procedures                                                               |  | 34  
|PART II. |  | OTHER INFORMATION                                                                     |  |     
|Item 4.  |  | Submission of Matters to a Vote of Security Holders                                   |  | 35  
|Item 6.  |  | Exhibits and Reports on Form 8-K                                                      |  | 35  

2



---



##### Table of Contents






PART I. FINANCIAL INFORMATION




Item 1.    FINANCIAL STATEMENTS




INDEPENDENT ACCOUNTANTS REPORT

Board of Directors and Shareholders
AVANIR Pharmaceuticals

We have reviewed the accompanying consolidated balance sheet of AVANIR
Pharmaceuticals and subsidiary as of March 31, 2003 and the related
consolidated statements of operations and cash flows for the three-month and
six-month periods ended March 31, 2003 and 2002. These financial statements
are the responsibility of the Companys management.

We conducted our review in accordance with standards established by the
American Institute of Certified Public Accountants. A review of interim
financial information consists principally of applying analytical procedures to
financial data and of making inquiries of persons responsible for financial and
accounting matters. It is substantially less in scope than an audit conducted
in accordance with auditing standards generally accepted in the United States
of America, the objective of which is the expression of an opinion regarding
the financial statements taken as a whole. Accordingly, we do not express such
an opinion.

Based on our review, we are not aware of any material modifications that should
be made to such consolidated financial statements for them to be in conformity
with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with auditing standards generally
accepted in the United States of America, the consolidated balance sheet of the
Company as of September 30, 2002 and the related consolidated statements of
operations, shareholders equity and cash flows for the year then ended (not
presented herein); and in our report dated December 24, 2002, we expressed an
unqualified opinion on those financial statements. In our opinion, the
information set forth in the accompanying consolidated balance sheet as of
September 30, 2002 is fairly stated, in all material respects, in relation to
the consolidated balance sheet from which it has been derived.

DELOITTE & TOUCHE LLP

San Diego, California
May 7, 2003

3



---



##### Table of Contents






AVANIR Pharmaceuticals

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |               |            |            |            | 
|-------------------------------------- | -------------------------------------------------------------------------------- | ------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------- | ---------- | ---------- | --------- | ------------- | ---------- | ---------- | ---------- | 
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            | March 31,  |           | September 30,
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            | 2003       |           | 2002         
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|ASSETS                                 |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|Current assets:                        |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       | Cash and cash equivalents                                                        |                           | $                                                                                                                                                             | 16,652,884                 |            |            | $         | 8,630,547     |           
|                                       | Short-term investments in securities                                             |                           |                                                                                                                                                               | 1,602,098                  |            |            |           | 695,840       |           
|                                       | Receivables, net                                                                 |                           |                                                                                                                                                               | 218,525                    |            |            |           | 1,098,954     |           
|                                       | Inventory                                                                        |                           |                                                                                                                                                               | 235,024                    |            |            |           | 238,126       |           
|                                       | Prepaid expenses                                                                 |                           |                                                                                                                                                               | 947,181                    |            |            |           | 683,111       |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       |                                                                                  | Total current assets      |                                                                                                                                                               |                            | 19,655,712 |            |           |               | 11,346,578 |           
|Investments in securities              |                                                                                  |                           | 694,235                                                                                                                                                       |                            |            |            | 2,986,023 |              
|Restricted investments                 |                                                                                  |                           | 856,597                                                                                                                                                       |                            |            |            | 856,597   |              
|Property and equipment, net            |                                                                                  |                           | 6,599,634                                                                                                                                                     |                            |            |            | 3,180,966 |              
|Intangible assets, net                 |                                                                                  |                           | 1,859,330                                                                                                                                                     |                            |            |            | 1,659,418 |              
|Other assets                           |                                                                                  |                           | 303,347                                                                                                                                                       |                            |            |            | 303,347   |              
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       | TOTAL ASSETS                                                                     |                           | $                                                                                                                                                             | 29,968,855                 |            |            | $         | 20,332,929    |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |               |           
|LIABILITIES AND SHAREHOLDERS EQUITY   |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|Current liabilities:                   |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       | Accounts payable                                                                 |                           | $                                                                                                                                                             | 2,936,467                  |            |            | $         | 2,705,606     |           
|                                       | Accrued expenses and other liabilities                                           |                           |                                                                                                                                                               | 1,537,187                  |            |            |           | 1,598,625     |           
|                                       | Accrued compensation and payroll taxes                                           |                           |                                                                                                                                                               | 573,306                    |            |            |           | 462,118       |           
|                                       | Loan payable                                                                     |                           |                                                                                                                                                               | 72,428                     |            |            |           | 299,980       |           
|                                       | Current portion of deferred revenue                                              |                           |                                                                                                                                                               | 2,372,644                  |            |            |           | 233,333       |           
|                                       | Current portion of capital lease obligations                                     |                           |                                                                                                                                                               | 134,739                    |            |            |           | 128,833       |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       |                                                                                  | Total current liabilities |                                                                                                                                                               |                            | 7,626,771  |            |           |               | 5,428,495  |           
|                                       | Deferred revenue, net of current portion                                         |                           |                                                                                                                                                               | 17,449,244                 |            |            |           |              |           
|                                       | Capital lease obligations, net of current portion                                |                           |                                                                                                                                                               | 265,460                    |            |            |           | 323,764       |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       |                                                                                  | Total liabilities         |                                                                                                                                                               |                            | 25,341,475 |            |           |               | 5,752,259  |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|CONTINGENCIES (Note 13)                |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|REDEEMABLE CONVERTIBLE PREFERRED STOCK |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       | Series D  no par value, 500 shares authorized; 50 shares
issued and outstanding |                           |                                                                                                                                                               | 530,307                    |            |            |           | 521,189       |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|SHAREHOLDERS EQUITY                   |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       | Preferred stock  no par value, 9,999,500 shares authorized:                     |                           |                                                                                                                                                               |                            |            |            |           |               |           
|                                       |                                                                                  |                           | Series C Junior Participating - 1,000,000 shares
authorized; no shares issued or outstanding                                                                  |                            |            |           |           |               |            |           |           
|                                       | Common stock  no par value:                                                     |                           |                                                                                                                                                               |                            |            |            |           |               |           
|                                       |                                                                                  |                           | Class A - 99,288,000 shares authorized; 58,427,733
and 58,270,533 shares issued and outstanding as of
March 31, 2003 and September 30, 2002, respectively     |                            |            | 87,307,812 |           |               |            | 87,053,257 |           
|                                       |                                                                                  |                           | Class B - 712,000 shares authorized; 13,500 shares
issued and outstanding as of March 31, 2003 and
September 30, 2002 (convertible into Class A common
stock) |                            |            | 8,395      |           |               |            | 8,395      |           
|                                       | Accumulated deficit                                                              |                           |                                                                                                                                                               | (83,227,929                | )          |            |           | (73,002,878   | )         
|                                       | Accumulated other comprehensive income                                           |                           |                                                                                                                                                               | 8,795                      |            |            |           | 707           |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       |                                                                                  |                           |                                                                                                                                                               | Total shareholders equity |            |            | 4,097,073 |               |            |            | 14,059,481 | 
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |              
|                                       | TOTAL LIABILITIES AND SHAREHOLDERS EQUITY                                       |                           | $                                                                                                                                                             | 29,968,855                 |            |            | $         | 20,332,929    |           
|                                       |                                                                                  |                           |                                                                                                                                                               |                            |            |            |           |               |           

See notes to consolidated financial statements.

4



---



##### Table of Contents






AVANIR Pharmaceuticals

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |            |           | 
|----------------------------------------------------- | ----------------------------------------------------------------------- | ------------------------ | ---------- | ------------------ | --------- | ---------------- | ---------- | ---------- | --------- | ---- | ----------- | ----------- | ---------- | - | ---------- | ---------- | --------- | 
|                                                      |                                                                         |                          |            | Three months ended |           | Six months ended
|                                                      |                                                                         |                          |            | March 31,          |           | March 31,       
|                                                      |                                                                         |                          |            |                    |           |                 
|                                                      |                                                                         |                          |            | 2003               |           | 2002             |            | 2003       |           | 2002
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |     
|REVENUES:                                             |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      | Research contracts and licenses                                         |                          | $          |                   |           |                  | $          | 17,500     |           |      | $           | 50,000      |            |   | $          | 5,084,167  |          
|                                                      | Royalties and sale of royalty rights                                    |                          |            | 481,450            |           |                  |            | 719,752    |           |      |             | 1,074,745   |            |   |            | 1,783,300  |          
|                                                      | Government research grants                                              |                          |            | 140,193            |           |                  |            | 1,126      |           |      |             | 298,604     |            |   |            | 1,126      |          
|                                                      | Product sales                                                           |                          |            |                   |           |                  |            |           |           |      |             | 17,400      |            |   |            |           |          
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      |                                                                         | Total revenues           |            |                    | 621,643   |                  |            |            | 738,378   |      |             |             | 1,440,749  |   |            |            | 6,868,593 | 
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|OPERATING EXPENSES:                                   |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      | Research and development                                                |                          |            | 4,860,280          |           |                  |            | 3,164,908  |           |      |             | 8,471,902   |            |   |            | 5,511,767  |          
|                                                      | General and administrative                                              |                          |            | 1,211,338          |           |                  |            | 1,078,971  |           |      |             | 2,291,884   |            |   |            | 2,033,039  |          
|                                                      | Sales and marketing                                                     |                          |            | 606,339            |           |                  |            | 360,765    |           |      |             | 1,031,468   |            |   |            | 680,797    |          
|                                                      | Cost of product sales                                                   |                          |            |                   |           |                  |            |           |           |      |             | 3,102       |            |   |            |           |          
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      |                                                                         | Total operating expenses |            |                    | 6,677,957 |                  |            |            | 4,604,644 |      |             |             | 11,798,356 |   |            |            | 8,225,603 | 
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|LOSS FROM OPERATIONS                                  |                                                                         |                          | (6,056,314 | )                  |           |                  | (3,866,266 | )          |           |      | (10,357,607 | )           |            |   | (1,357,010 | )         
|                                                      | Interest income                                                         |                          |            | 85,128             |           |                  |            | 180,911    |           |      |             | 153,150     |            |   |            | 368,826    |          
|                                                      | Other income                                                            |                          |            | 6,013              |           |                  |            | 4,008      |           |      |             | 11,859      |            |   |            | 86,948     |          
|                                                      | Interest expense                                                        |                          |            | (12,761            | )         |                  |            | (18,241    | )         |      |             | (23,335     | )          |   |            | (32,843    | )        
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|NET LOSS                                              |                                                                         | $                        | (5,977,934 | )                  |           | $                | (3,699,588 | )          |           | $    | (10,215,933 | )           |            | $ | (934,079   | )         
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|NET LOSS ATTRIBUTABLE TO COMMON
SHAREHOLDERS:         |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      | Net loss                                                                |                          | $          | (5,977,934         | )         |                  | $          | (3,699,588 | )         |      | $           | (10,215,933 | )          |   | $          | (934,079   | )        
|                                                      | Dividends on redeemable convertible
preferred stock                     |                          |            | (6,250             | )         |                  |            | (6,250     | )         |      |             | (12,500     | )          |   |            | (12,500    | )        
|                                                      | Accretion of discount related to
redeemable convertible preferred
stock |                          |            | (4,509             | )         |                  |            | (4,509     | )         |      |             | (9,118      | )          |   |            | (9,118     | )        
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|NET LOSS ATTRIBUTABLE TO COMMON
SHAREHOLDERS          |                                                                         | $                        | (5,988,693 | )                  |           | $                | (3,710,347 | )          |           | $    | (10,237,551 | )           |            | $ | (955,697   | )         
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|NET LOSS PER SHARE:                                   |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      | BASIC AND DILUTED                                                       |                          | $          | (0.10              | )         |                  | $          | (0.06      | )         |      | $           | (0.18       | )          |   | $          | (0.02      | )        
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|WEIGHTED AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING: |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           
|                                                      | BASIC AND DILUTED                                                       |                          |            | 58,352,406         |           |                  |            | 58,240,466 |           |      |             | 58,324,174  |            |   |            | 58,133,775 |          
|                                                      |                                                                         |                          |            |                    |           |                  |            |            |           |      |             |             |            |   |            |           

See notes to consolidated financial statements.

5



---



##### Table of Contents






AVANIR Pharmaceuticals

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |            |         |         |            |  
|------------------------------------------------------------------------ | ------------------------------------------------------------------------------- | --------------------------------------------- | -------------------------------------- | ---------------------------------------------------- | ------ | ---------------- | ---------- | ---------- | ------- | ------- | ---------- | -
|                                                                         |                                                                                 |                                               |                                        |                                                      |        | Six Months Ended
|                                                                         |                                                                                 |                                               |                                        |                                                      |        | March 31,       
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                 
|                                                                         |                                                                                 |                                               |                                        |                                                      |        | 2003             |            | 2002      
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|OPERATING ACTIVITIES:                                                    |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         | Net loss                                                                        |                                               | $                                      | (10,215,933                                          | )      |                  | $          | (934,079   | )      
|                                                                         | Adjustments to reconcile net loss to net cash provided by
operating activities: |                                               |                                        |                                                      |        |                  |            |            |        
|                                                                         | Depreciation and amortization                                                   |                                               |                                        | 383,954                                              |        |                  |            | 275,654    |        
|                                                                         | Compensation paid with common stock and stock options                           |                                               |                                        | 181,706                                              |        |                  |            | 89,298     |        
|                                                                         | Loss on disposal of assets                                                      |                                               |                                        | 1,100                                                |        |                  |            | 485        |        
|                                                                         | Changes in assets and liabilities:                                              |                                               |                                        |                                                      |        |                  |            |            |        
|                                                                         |                                                                                 |                                               | Receivables, net                       |                                                      |        | 880,429          |            |            |         | (32,958 | )         
|                                                                         |                                                                                 |                                               | Inventory                              |                                                      |        | 3,102            |            |            |         |        |           
|                                                                         |                                                                                 |                                               | Prepaid expenses and other assets      |                                                      |        | (264,070         | )          |            |         | (50,902 | )         
|                                                                         |                                                                                 |                                               | Accounts payable                       |                                                      |        | 230,861          |            |            |         | 465,610 |           
|                                                                         |                                                                                 |                                               | Accrued expenses and other liabilities |                                                      |        | (61,438          | )          |            |         | 341,209 |           
|                                                                         |                                                                                 |                                               | Accrued compensation and payroll taxes |                                                      |        | 111,188          |            |            |         | 60,867  |           
|                                                                         |                                                                                 |                                               | Deferred revenue                       |                                                      |        | 19,588,555       |            |            |         |        |           
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         |                                                                                 |                                               |                                        | Net cash provided by operating activities:           |        |                  | 10,839,454 |            |         |         | 215,184    |  
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|INVESTING ACTIVITIES:                                                    |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         | Investments in securities                                                       |                                               |                                        | (706,382                                             | )      |                  |            | (8,601,136 | )      
|                                                                         | Proceeds from sales and maturities of investments in securities                 |                                               |                                        | 2,100,000                                            |        |                  |            | 1,200,000  |        
|                                                                         | Patent costs                                                                    |                                               |                                        | (234,306                                             | )      |                  |            | (250,570   | )      
|                                                                         | Construction in progress                                                        |                                               |                                        | (2,986,803                                           | )      |                  |            |           |        
|                                                                         | Purchases of property and equipment                                             |                                               |                                        | (782,525                                             | )      |                  |            | (300,111   | )      
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         |                                                                                 |                                               |                                        | Net cash used for investing activities               |        |                  | (2,610,016 | )          |         |         | (7,951,817 | )
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|FINANCING ACTIVITIES:                                                    |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         | Proceeds from issuance of common stock                                          |                                               |                                        | 85,350                                               |        |                  |            | 255,054    |        
|                                                                         | Dividends paid on preferred stock                                               |                                               |                                        | (12,500                                              | )      |                  |            | (12,500    | )      
|                                                                         | Payments on loans and capital lease obligations                                 |                                               |                                        | (279,951                                             | )      |                  |            | (197,785   | )      
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |            |        
|                                                                         |                                                                                 |                                               |                                        | Net cash provided by (used for) financing activities |        |                  | (207,101   | )          |         |         | 44,769     |  
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |            |        
|Net increase (decrease) in cash and cash equivalents                     |                                                                                 |                                               | 8,022,337                              |                                                      |        |                  | (7,691,864 | )         
|Cash and cash equivalents at beginning of period                         |                                                                                 |                                               | 8,630,547                              |                                                      |        |                  | 16,542,545 |           
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |            |        
|Cash and cash equivalents at end of period                               |                                                                                 | $                                             | 16,652,884                             |                                                      |        | $                | 8,850,681  |           
|                                                                         |                                                                                 |                                               |                                        |                                                      |        |                  |            |            |        
|SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:                       |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         |                                                                                 | Interest paid                                 |                                        | $                                                    | 23,335 |                  |            | $          | 32,843  |        
|SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING
ACTIVITIES: |                                                                                 |                                               |                                        |                                                      |        |                  |            |           
|                                                                         |                                                                                 | Acquisition of equipment under capital leases |                                        | $                                                    |       |                  |            | $          | 110,641 |        

See notes to consolidated financial statements.

6



---



##### Table of Contents






AVANIR Pharmaceuticals

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



|1. |  | BASIS OF PRESENTATION
|-- |  | ---------------------

AVANIR Pharmaceuticals (AVANIR, we or the Company) has prepared the
unaudited consolidated financial statements in this quarterly report in
accordance with the instructions to Form 10-Q adopted under the Securities
Exchange Act of 1934. Certain information and footnote disclosures normally
included in consolidated financial statements prepared in accordance with
accounting principles generally accepted in the United States have been
condensed or omitted pursuant to such rules and regulations. These unaudited
consolidated financial statements should be read with our audited consolidated
financial statements and the accompanying notes included in our Annual Report
on Form 10-K for the fiscal year ended September 30, 2002. In our opinion, all
adjustments (consisting only of normal recurring adjustments) necessary to
present a fair statement of our financial position as of March 31, 2003 and
September 30, 2002, and the results of operations for the three and six-month
periods ended March 31, 2003 and 2002, have been made. The results of
operations for the three and six-month periods ended March 31, 2003 are not
necessarily indicative of the results for the fiscal year ending September 30,
2003 or any future periods.



|2. |  | STOCK-BASED COMPENSATION
|-- |  | ------------------------

In December 2002, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards No. 148 (SFAS No. 148),
Accounting for Stock-based Compensation  Transition and Disclosure, an
Amendment of FASB Statement No. 123. SFAS No. 148 amends the disclosure
requirements of SFAS No. 123 to require prominent disclosures in both annual
and interim financial reports about the method of accounting for stock-based
compensation and the effect of the method used on reported results. SFAS No.
123, as amended, encourages, but does not require, companies to record
compensation cost for stock-based employee compensation at fair value. The
Company has chosen to continue to account for stock-based compensation using
the intrinsic value method prescribed in Accounting Principles Board (APB)
Opinion No. 25, Accounting for Stock Issued to Employees, and related
interpretations for all periods presented. Accordingly, compensation costs for
stock options is measured as the excess, if any, of the fair value of the
Companys stock at the date of the grant over the amount an employee must pay
to acquire the stock.

The following table summarizes the impact on the Companys net loss had
compensation costs been determined based upon the fair value at the grant date
for awards under the stock option plans consistent with the methodology
prescribed under SFAS No. 123.

|                                                                                                                |                                 |                                                        |            |                              |            |                            |            |       |            |      |             |       |             |   |            |       |            |  
|--------------------------------------------------------------------------------------------------------------- | ------------------------------- | ------------------------------------------------------ | ---------- | ---------------------------- | ---------- | -------------------------- | ---------- | ----- | ---------- | ---- | ----------- | ----- | ----------- | - | ---------- | ----- | ---------- | -
|                                                                                                                |                                 |                                                        |            | Three Months Ended March 31, |            | Six Months Ended March 31,
|                                                                                                                |                                 |                                                        |            |                              |            |                           
|                                                                                                                |                                 |                                                        |            | 2003                         |            | 2002                       |            | 2003  |            | 2002
|                                                                                                                |                                 |                                                        |            |                              |            |                            |            |       |            |     
|Net loss attributable to common
shareholders, as reported                                                       |                                 | $                                                      | (5,988,693 | )                            |            | $                          | (3,710,347 | )     |            | $    | (10,237,551 | )     |             | $ | (955,697   | )    
|Add: Stock-based employee
compensation included in
reported net loss attributable
to common shareholders        |                                 |                                                        | 132,570    |                              |            |                            | 42,759     |       |            |      | 175,743     |       |             |   | 85,931     |      
|Deduct: Total stock-based
employee compensation expense
determined under fair value
based method for all awards |                                 |                                                        | (527,883   | )                            |            |                            | (732,969   | )     |            |      | (1,043,735  | )     |             |   | (1,278,115 | )    
|                                                                                                                |                                 |                                                        |            |                              |            |                            |            |       |            |      |             |       |             |   |            |      
|                                                                                                                |                                 | Pro forma net loss
attributable to common
shareholders |            | $                            | (6,384,006 | )                          |            | $     | (4,400,557 | )    |             | $     | (11,105,543 | ) |            | $     | (2,147,881 | )
|                                                                                                                |                                 |                                                        |            |                              |            |                            |            |       |            |      |             |       |             |   |            |      
|Net loss per share:                                                                                             |                                 |                                                        |            |                              |            |                            |            |       |            |      |             |       |             |   |            |      
|                                                                                                                | Basic and diluted  as reported |                                                        | $          | (0.10                        | )          |                            | $          | (0.06 | )          |      | $           | (0.18 | )           |   | $          | (0.02 | )         
|                                                                                                                | Basic and diluted  pro forma   |                                                        | $          | (0.11                        | )          |                            | $          | (0.08 | )          |      | $           | (0.19 | )           |   | $          | (0.04 | )         

7



---



##### Table of Contents



The Company accounts for stock options granted to non-employees using the fair
value method. Compensation expense for options granted to non-employees has
been determined in accordance with Emerging Issues Task Force (EITF) No.
96-18, Accounting for Equity Instruments That Are Issued to Other Than
Employees for Acquiring, or in Conjunction with Selling, Goods or Services, as
the fair value of the consideration received or the fair value of the equity
instruments issued, whichever is more reliably measurable.



|3. |  | RECLASSIFICATIONS
|-- |  | -----------------

Certain amounts from the prior period have been reclassified to conform with
the current period presentation.



|4. |  | BALANCE SHEET DETAILS
|-- |  | ---------------------

The following tables provide details of selected balance sheet items.

Receivables.Receivables consist of the following:

|            |  |                |         |                    |  |     |        |       |  |          |         |               |  |   |           |  |  |   |   |  |  |   |           | 
|----------- |  | -------------- | ------- | ------------------ |  | --- | ------ | ----- |  | -------- | ------- | ------------- |  | - | --------- |  |  | - | - |  |  | - | --------- | 
|            |  | March 31, 2003 |         | September 30, 2002
|            |  |                |         |                   
|            |  | Gross          |         | Allowance for      |  |     |        |       |  | Gross    |         | Allowance for |  |   |           | 
|            |  | Carrying       |         | Doubtful           |  |     |        |       |  | Carrying |         | Doubtful      |  |   |           | 
|            |  | Value          |         | Accounts           |  | Net |        | Value |  | Accounts |         | Net          
|            |  |                |         |                    |  |     |        |       |  |          |         |              
|Receivables |  | $              | 223,897 |                    |  | $   | (5,372 | )     |  | $        | 218,525 |               |  | $ | 1,098,954 |  |  | $ |  |  |  | $ | 1,098,954 | 
|            |  |                |         |                    |  |     |        |       |  |          |         |               |  |   |           |  |  |   |   |  |  |   |           | 

Property and Equipment.Property and equipment consist of the following:

|                                          |                              |   |                |           |                    |   |            |            |       |   |              |           |             |   |           |           |  |   |          |            |   |   |           |           | 
|----------------------------------------- | ---------------------------- | - | -------------- | --------- | ------------------ | - | ---------- | ---------- | ----- | - | ------------ | --------- | ----------- | - | --------- | --------- |  | - | -------- | ---------- | - | - | --------- | --------- | 
|                                          |                              |   | March 31, 2003 |           | September 30, 2002
|                                          |                              |   |                |           |                   
|                                          |                              |   | Gross          |           |                    |   |            |            |       |   |              |           | Gross       |   |           |           |  |   |          |            |  
|                                          |                              |   | Carrying       |           | Accumulated        |   |            |            |       |   | Carrying     |           | Accumulated |   |           |           | 
|                                          |                              |   | Value          |           | Depreciation       |   | Net        |            | Value |   | Depreciation |           | Net        
|                                          |                              |   |                |           |                    |   |            |            |       |   |              |           |            
|Research and
development equipment        |                              | $ | 2,652,899      |           |                    | $ | (1,060,310 | )          |       | $ | 1,592,589    |           |             | $ | 2,420,028 |           |  | $ | (867,991 | )          |   | $ | 1,552,037 |          
|Computer equipment and
related software   |                              |   | 1,004,736      |           |                    |   | (306,767   | )          |       |   | 697,969      |           |             |   | 851,952   |           |  |   | (238,199 | )          |   |   | 613,753   |          
|Leasehold improvements                    |                              |   | 871,196        |           |                    |   | (234,521   | )          |       |   | 636,675      |           |             |   | 866,318   |           |  |   | (175,410 | )          |   |   | 690,908   |          
|Office equipment,
furniture, and
fixtures |                              |   | 291,080        |           |                    |   | (150,577   | )          |       |   | 140,503      |           |             |   | 254,731   |           |  |   | (128,557 | )          |   |   | 126,174   |          
|Construction in
progress                  |                              |   | 3,531,898      |           |                    |   |           |            |       |   | 3,531,898    |           |             |   | 198,094   |           |  |   |         |            |   |   | 198,094   |          
|                                          |                              |   |                |           |                    |   |            |            |       |   |              |           |             |   |           |           |  |   |          |            |   |   |           |          
|                                          | Total property and
equipment |   | $              | 8,351,809 |                    |   | $          | (1,752,175 | )     |   | $            | 6,599,634 |             |   | $         | 4,591,123 |  |   | $        | (1,410,157 | ) |   | $         | 3,180,966 | 
|                                          |                              |   |                |           |                    |   |            |            |       |   |              |           |             |   |           |           |  |   |          |            |   |   |           |          

Intangible Assets.Effective October 1, 2002, the Company adopted SFAS No.
142, Goodwill and Other Intangible Assets, which requires goodwill and other
intangible assets that have indefinite useful lives to no longer be amortized;
however, these assets must be reviewed at least annually for impairment.
Intangible assets with indefinite useful lives consist of costs of trademarks
for AVANIR and Xenerex and similar names intended for use or potential use in
the United States and the rest-of-the-world. Intangible assets with finite
lives continue to be amortized over their useful lives for the three and
six-month periods ended March 31, and are evaluated for impairment whenever
events or changes in circumstances indicate that their carrying value may not
be recoverable under SFAS No. 144, Accounting for Impairment or

8



---



##### Table of Contents



Disposal of Long-lived Assets. AVANIRs amortizable intangible assets consist
of the costs of patents, patent applications, and licenses.

Intangible assets, consisting of both intangible assets with finite and
indefinite useful lives, are as follows:

|                                               |                             |   |                |           |                    |   |          |          |       |   |              |           |             |   |           |         |  |   |          |          |   |   |           |         | 
|---------------------------------------------- | --------------------------- | - | -------------- | --------- | ------------------ | - | -------- | -------- | ----- | - | ------------ | --------- | ----------- | - | --------- | ------- |  | - | -------- | -------- | - | - | --------- | ------- | 
|                                               |                             |   | March 31, 2003 |           | September 30, 2002
|                                               |                             |   |                |           |                   
|                                               |                             |   | Gross          |           |                    |   |          |          |       |   |              |           | Gross       |   |           |         |  |   |          |          |  
|                                               |                             |   | Carrying       |           | Accumulated        |   |          |          |       |   | Carrying     |           | Accumulated |   |           |         | 
|                                               |                             |   | Value          |           | Amortization       |   | Net      |          | Value |   | Amortization |           | Net        
|                                               |                             |   |                |           |                    |   |          |          |       |   |              |           |            
|Intangible assets with
finite lives:           |                             |   |                |           |                    |   |          |          |       |   |              |           |             |   |           |         |  |   |          |          |   |   |           |        
|                                               | Patent applications
pending |   | $              | 1,165,112 |                    |   | $        |         |       |   | $            | 1,165,112 |             |   | $         | 966,781 |  |   | $        |         |   |   | $         | 966,781 | 
|                                               | Patents                     |   |                | 783,246   |                    |   |          | (221,859 | )     |   |              | 561,387   |             |   |           | 741,175 |  |   |          | (192,190 | ) |   |           | 548,985 | 
|                                               | Licenses                    |   |                | 41,216    |                    |   |          | (12,254  | )     |   |              | 28,962    |             |   |           | 41,215  |  |   |          | (6,445   | ) |   |           | 34,770  | 
|                                               | Licenses pending            |   |                |          |                    |   |          |         |       |   |              |          |             |   |           | 22,101  |  |   |          |         |   |   |           | 22,101  | 
|                                               |                             |   |                |           |                    |   |          |          |       |   |              |           |             |   |           |         |  |   |          |          |   |   |           |        
|Total intangible
assets with finite
lives      |                             |   | 1,989,574      |           |                    |   | (234,113 | )        |       |   | 1,755,461    |           |             |   | 1,771,272 |         |  |   | (198,635 | )        |   |   | 1,572,637 |        
|Intangible assets with
indefinite useful
lives |                             |   | 103,869        |           |                    |   |         |          |       |   | 103,869      |           |             |   | 86,781    |         |  |   |         |          |   |   | 86,781    |        
|                                               |                             |   |                |           |                    |   |          |          |       |   |              |           |             |   |           |         |  |   |          |          |   |   |           |         | 
|Total intangible assets                        |                             | $ | 2,093,443      |           |                    | $ | (234,113 | )        |       | $ | 1,859,330    |           |             | $ | 1,858,053 |         |  | $ | (198,635 | )        |   | $ | 1,659,418 |        
|                                               |                             |   |                |           |                    |   |          |          |       |   |              |           |             |   |           |         |  |   |          |          |   |   |           |        

Amortization expense related to amortizable intangible assets was $20,000 and
$36,000 for the three and six-month periods ended March 31, 2003, and $12,000
and $24,000 for the same periods, respectively, in the prior year. Based
solely on the amortizable intangible assets as of March 31, 2003, the estimated
annual amortization expense of intangible assets for the fiscal years ending
September 30 is as shown in the following table. Actual amortization expense
to be reported in future periods could differ from these estimates as a result
of acquisitions, divestitures, and other relevant factors.

|                                 |          |   |           |           | 
|-------------------------------- | -------- | - | --------- | --------- | 
|Amortization Expense for        
|Fiscal Year Ending September 30,
|                                
|2003                             |          | $ | 30,260    |          
|2004                             |          |   | 61,059    |          
|2005                             |          |   | 60,574    |          
|2006                             |          |   | 60,109    |          
|2007                             |          |   | 58,842    |          
|Thereafter                       |          |   | 319,505   |          
|                                 |          |   |           |          
|                                 | Subtotal |   |           | 590,349   | 
|Patent applications pending      |          |   | 1,165,112 |          
|                                 |          |   |           |          
|                                 | Total    |   | $         | 1,755,461 | 
|                                 |          |   |           |          



|5. |  | USE OF ESTIMATES
|-- |  | ----------------

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities
as of the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from
those estimates.

9



---



##### Table of Contents





|6. |  | INVENTORY
|-- |  | ---------

Inventory is stated at the lower of cost (first-in, first-out) or market.
Inventory consists primarily of the raw material docosanol, which is the active
ingredient in docosanol 10% cream. Docosanol in its present form as stored by
the Company has a substantial shelf life, a relatively stable value and
long-term use, and carries a low risk of becoming excess inventory or obsolete.
AVANIR does not own or store any docosanol 10% cream in its finished product
form. The Company and one of its licensees receive raw materials from a single
supplier. AVANIR also supplies several other licensees with raw materials from
the same supplier. The inability of a sole supplier to fulfill supply
requirements of the Company or its licensees could materially impact future
operating results. AVANIR also holds in inventory small quantities of
dextromethorphan and quinidine, compounds useful in the manufacture of
Neurodex. AVANIR is developing Neurodex as a potential treatment for
pseudobulbar affect and neuropathic pain.



|7. |  | ASSET SALE
|-- |  | ----------

On December 24, 2002, AVANIR sold an undivided interest in its Abreva® license
agreement with SB Pharmco Puerto Rico, Inc. (SB or GlaxoSmithKline) to Drug
Royalty USA, Inc. (Drug Royalty USA). Under the terms of the Drug Royalty
USA agreement, Drug Royalty USA acquired the rights to all royalties accruing
after September 30, 2002 from the sale of Abreva for cold sores in the United
States and Canada payable under the Abreva license agreement, subject to
AVANIRs right to receive 50% of all such royalties payable on sales of Abreva
over $62 million per year. Drug Royalty USA paid AVANIR $20.5 million at the
closing and agreed to pay an additional $3.6 million upon AVANIRs receipt from
the United States Patent and Trademark Office of a grant of patent term
extension for U.S. Patent Number 4,874,794. In connection with the sale,
AVANIR and Drug Royalty USA entered into a security agreement pursuant to which
AVANIR granted Drug Royalty USA a security interest in AVANIRs United States
and Canadian patents related to the treatment of cold sores. (See Note 14,
Subsequent Event.)

AVANIR retains all rights to develop and license docosanol 10% cream (or
Abreva, as marketed by SBs parent, GlaxoSmithKline) outside the United States
and Canada for the treatment of cold sores. AVANIR also retains all rights to
develop and license docosanol 10% cream worldwide for all other indications,
subject to certain rights of SB in the United States and Canada.

In recording the sale transaction, AVANIR increased cash by $20.4 million (net
of transaction costs), reduced accrued expenses by $301,000 in connection with
the forgiveness of a related advance, and recorded deferred revenue in the
amount of $20.7 million. We recorded the initial net proceeds of the
transaction as deferred revenue because of our ongoing involvement in earning
future revenues under our license agreement with SB. AVANIR is recognizing the
deferred revenue amount as revenue over the life of the Drug Royalty USA
agreement. Revenue recognition is being determined under the units-of-revenue
method. Under this method, the amount of deferred revenue to be recognized as
revenue in each period is calculated by multiplying (i) the ratio of the
royalty payments due to Drug Royalty USA for the period to the total remaining
royalties that we expect SB will pay Drug Royalty USA over the term of the
agreement, by (ii) the unamortized deferred revenue amount. The portion of
deferred revenue classified as part of current liabilities represents the
amount AVANIR expects to realize as revenue within the next 12 months.

10



---



##### Table of Contents



The following table sets forth the deferred revenue recorded from the sale to
Drug Royalty USA of rights to future Abreva royalties and other deferred
revenue balances as of March 31, 2003 and September 30, 2002.

|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |            |            | 
|----------------------------------------- | --------------------------------------------- | ----------------------------- | ---------- | ------------- | ---------- | ---------- | ------- | ------- | ------- | - | ---------- | ---------- | ---------- | 
|                                          |                                               |                               |            | Drug Royalty  |            | Other      |         |         |         |  
|                                          |                                               |                               |            | USA Agreement |            | Agreements |         | Total  
|                                          |                                               |                               |            |               |            |            |         |        
|Deferred revenue as of September 30, 2002 |                                               | $                             |           |               |            | $          | 233,333 |         |         | $ | 233,333    |           
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           
|Changes during the period:                |                                               |                               |            |               |            |            |         |         |         |   |            |           
|                                          | Proceeds from sale of future Abreva royalties |                               |            | 20,500,000    |            |            |         |        |         |   |            | 20,500,000 |           
|                                          | Less cost of transaction                      |                               |            | (143,982      | )          |            |         |        |         |   |            | (143,982   | )         
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           
|                                          |                                               | Net proceeds                  |            |               | 20,356,018 |            |         |         |        |   |            |            | 20,356,018 | 
|                                          | Forgiveness of a related advance              |                               |            | 300,912       |            |            |         |        |         |   |            | 300,912    |           
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           
|                                          |                                               | Additions to deferred revenue |            |               | 20,656,930 |            |         |         |        |   |            |            | 20,656,930 | 
|                                          | Recognized as revenues during the period      |                               |            | (1,068,375    | )          |            |         |        |         |   |            | (1,068,375 | )         
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           
|Deferred revenue as of March 31, 2003     |                                               | $                             | 19,588,555 |               |            | $          | 233,333 |         |         | $ | 19,821,888 |           
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           
|Classified as:                            |                                               |                               |            |               |            |            |         |         |         |   |            |           
|                                          | Current portion of deferred revenue           |                               | $          | 2,139,311     |            |            | $       | 233,333 |         |   | $          | 2,372,644  |           
|                                          | Deferred revenue, net of current portion      |                               |            | 17,449,244    |            |            |         |        |         |   |            | 17,449,244 |           
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           
|                                          |                                               | Total deferred revenue        |            | $             | 19,588,555 |            |         | $       | 233,333 |   |            | $          | 19,821,888 | 
|                                          |                                               |                               |            |               |            |            |         |         |         |   |            |           



|8. |  | REVENUE RECOGNITION
|-- |  | -------------------

Performance-based license fees.We recognize revenues from license fees when
the performance requirements have been met, the fee is fixed or determinable,
and collection of fees is probable. We defer revenues and recognize them
ratably over the life of the agreement when we have continuing obligations to
perform under the agreement.

Royalty revenues.We recognize royalty revenues from our licensed products when
earned. Net sales figures used for calculating royalties due to the Company
can often include deductions for costs of unsaleable returns, managed care
chargebacks, cash discounts, freight and warehousing, and miscellaneous
write-offs, which may vary over the course of the license agreement. Sales of
Abreva, if publicly reported by the licensees parent, GlaxoSmithKline, could
differ from net sales used in calculating royalties and in determining the
royalties earned in accordance with the license agreement. In agreements where
we have sold our rights to future royalties under license agreements and we
maintain continuing involvement in earning such royalties, we defer revenues
and recognize them ratably over the life of the license agreement.

Revenue arrangements with multiple deliverables.In certain circumstances, we
may enter into revenue arrangements whereby we are obligated to deliver to the
customer multiple products and/or services (multiple deliverables). Such
arrangements could include antibody generation services agreements and other
forms of research collaborations. In these transactions, we allocate the total
revenue to be earned under the arrangement among the various elements based on
their relative fair value. In the case of antibody generation services, the
allocation is based on customer-specific objective evidence of fair value. In
the case of other forms of research collaborations, milestone payments are
deferred and recognized ratably over the period of the obligation. We
recognize revenue related to the delivered products or services only if: (i)
the performance or service criteria are met; (ii) any undelivered products or
services are not essential to the functionality of the delivered products or
services; (iii) payment for the delivered products or services is not
contingent upon delivery of the remaining products or services; (iv) we have an
enforceable claim to receive the amount due in the event we do not deliver the
undelivered

11



---



##### Table of Contents



products or services; and (v) as discussed above, there is evidence of the fair
value for each of the undelivered products or services.

Federal research grant revenue.We recognize revenues from federal research
grants during the period in which the related expenditures are incurred.



|9. |  | INVESTMENTS
|-- |  | -----------

The following tables summarize the Companys investments in securities:

|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |           |           |  |  | 
|--------------------- | ----------------------- | -------------------------------- | --------------------- | --------- | --------- | --------- | --------- | ---------- | ------ | ---------- | - | ------ | ------ | - | - | --------- | --------- |  |  | 
|                      |                         |                                  |                       |           |           |           |           |            |        | Gross      |   | Gross  |        |   |   |          
|                      |                         |                                  |                       |           |           | Amortized |           | Unrealized |        | Unrealized |   | Fair  
|                      |                         |                                  |                       |           |           | Cost      |           | Gains (2)  |        | Losses (2) |   | Value 
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |       
|As of March 31, 2003: |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          
|                      | Certificates of deposit |                                  | $                     | 2,156,597 |           |           | $         | 16,854     |        |            | $ | (134   | )      |   | $ | 2,173,317 |          
|                      | Government securities   |                                  |                       | 987,538   |           |           |           |           |        |            |   | (7,925 | )      |   |   | 979,613   |          
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |           |          
|                      |                         | Total                            |                       | $         | 3,144,135 |           |           | $          | 16,854 |            |   | $      | (8,059 | ) |   | $         | 3,152,930 | 
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          
|Reported as:          |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          
|                      | Short-term investments: |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |           |          
|                      |                         | Classified as available-for-sale |                       | $         | 1,602,098 |           |           |            |        |            |   |        |        |   |   |           |           | 
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          
|                      | Long-term investments:  |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |           |          
|                      |                         | Classified as available-for-sale |                       |           | 694,235   |           |           |            |        |            |   |        |        |   |   |           |           | 
|                      |                         | Restricted investments (1)       |                       |           | 856,597   |           |           |            |        |            |   |        |        |   |   |           |           | 
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          
|                      |                         |                                  | Long-term investments |           |           | 1,550,832 |           |            |        |            |   |        |        |   |   |           |           |  | 
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          
|                      |                         |                                  |                       | Total     |           | $         | 3,152,930 |            |        |            |   |        |        |   |   |           |           |  |  | 
|                      |                         |                                  |                       |           |           |           |           |            |        |            |   |        |        |   |   |          

|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |           |           |  |  | 
|------------------------- | ----------------------- | -------------------------------- | ---------------------- | --------- | --------- | --------- | --------- | ---------- | ------ | ---------- | - | ------- | ------- | - | - | --------- | --------- |  |  | 
|                          |                         |                                  |                        |           |           |           |           |            |        | Gross      |   | Gross   |         |   |   |          
|                          |                         |                                  |                        |           |           | Amortized |           | Unrealized |        | Unrealized |   | Fair   
|                          |                         |                                  |                        |           |           | Cost      |           | Gains (3)  |        | Losses (3) |   | Value  
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |        
|As of September 30, 2002: |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          | Certificates of deposit |                                  | $                      | 2,056,597 |           |           | $         | 10,434     |        |            | $ |        |         |   | $ | 2,067,031 |          
|                          | Government securities   |                                  |                        | 2,281,156 |           |           |           | 3,173      |        |            |   | (12,900 | )       |   |   | 2,271,429 |          
|                          | Commercial paper        |                                  |                        | 200,000   |           |           |           | 5,542      |        |            |   |        |         |   |   | 205,542   |          
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          |                         | Total                            |                        | $         | 4,537,753 |           |           | $          | 19,149 |            |   | $       | (12,900 | ) |   | $         | 4,544,002 | 
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|Reported as:              |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          | Short-term investments: |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |           |          
|                          |                         | Classified as available-for-sale |                        | $         | 495,840   |           |           |            |        |            |   |         |         |   |   |           |           | 
|                          |                         | Classified as held-to-maturity   |                        |           | 200,000   |           |           |            |        |            |   |         |         |   |   |           |           | 
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          |                         |                                  | Short-term investments |           |           | 695,840   |           |            |        |            |   |         |         |   |   |           |           |  | 
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          | Long-term investments:  |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |           |          
|                          |                         | Classified as available-for-sale |                        |           | 2,986,023 |           |           |            |        |            |   |         |         |   |   |           |           | 
|                          |                         | Restricted investments (1)       |                        |           | 856,597   |           |           |            |        |            |   |         |         |   |   |           |           | 
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          |                         |                                  | Long-term investments  |           |           | 3,842,620 |           |            |        |            |   |         |         |   |   |           |           |  | 
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          
|                          |                         |                                  |                        | Total     |           | $         | 4,538,460 |            |        |            |   |         |         |   |   |           |           |  |  | 
|                          |                         |                                  |                        |           |           |           |           |            |        |            |   |         |         |   |   |          



|(1) |  | Restricted investments amounting to $856,597 as of March 31, 2003
and September 30, 2002 represent amounts that we pledged to our bank as
collateral for letters of credit that our bank issued in connection
with our leases of office and laboratory space.                                                
|--- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   
|(2) |  | Gross unrealized gains of $16,854 and gross unrealized losses of
$8,059 on government securities and certificates of deposit represent
an accumulated net unrealized gain of $8,795, which is reported as
Accumulated other comprehensive income on the consolidated balance
sheet as of March 31, 2003.   
|   
|(3) |  | Gross unrealized gains of $13,607 and gross unrealized losses of
$12,900 on government securities and certificates of deposit represent
an accumulated net unrealized gain of $707, which is reported as
Accumulated other comprehensive income on the consolidated balance
sheet as of September 30, 2002.

12



---



##### Table of Contents





|10. |  | COMPUTATION OF NET LOSS PER COMMON SHARE
|--- |  | ----------------------------------------

We compute basic net loss per common share by dividing the net loss
attributable to common shareholders by the weighted-average number of common
shares outstanding during the period (Basic EPS Method). We compute diluted
net loss per common share by dividing the net loss attributable to common
shareholders by the weighted-average number of common and dilutive common
equivalent shares outstanding during the period (Diluted EPS Method).
Dilutive common equivalent shares consist of shares issuable upon exercise of
stock options and warrants and conversion of preferred stock. In the
accompanying consolidated statements of operations, we have presented our net
loss per share for the three and six-month periods ended March 31, 2003 and
2002 using the Basic EPS Method and the Diluted EPS Method. The shares of
common stock issuable upon exercise of stock options and warrants and
conversion of preferred stock under the Diluted EPS method were excluded from
the three and six-month periods ended March 31, 2003 and 2002, as the inclusion
of such shares would have been anti-dilutive.

The following table provides a reconciliation from the basic to the diluted EPS
computations for the three and six-month periods ended March 31, 2003 and 2002:

|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |          |          |          |  
|------------------------------------------------------------------------------------- | ----------------------------------------------------------------------- | --------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------- | ---------- | ---------------------------- | ---------- | -------------------------- | ---------- | ---------- | ---------- | ---------- | ----------- | ----------- | ----------- | ---------- | -------- | -------- | -------- | -
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            | Three Months Ended March 31, |            | Six Months Ended March 31,
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                           
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            | 2003                         |            | 2002                       |            | 2003       |            | 2002      
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |           
|Numerator:                                                                            |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |         
|                                                                                      | Net loss                                                                |                                                                                         | $                                                                                     | (5,977,934 | )                            |            | $                          | (3,699,588 | )          |            | $          | (10,215,933 | )           |             | $          | (934,079 | )       
|Less:                                                                                 |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |         
|                                                                                      | Dividends on redeemable
convertible preferred stock                     |                                                                                         |                                                                                       | (6,250     | )                            |            |                            | (6,250     | )          |            |            | (12,500     | )           |             |            | (12,500  | )       
|                                                                                      | Accretion of discount related to
redeemable convertible preferred
stock |                                                                                         |                                                                                       | (4,509     | )                            |            |                            | (4,509     | )          |            |            | (9,118      | )           |             |            | (9,118   | )       
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |          |         
|                                                                                      |                                                                         |                                                                                         | Net loss attributable to
common shareholders for basic
earnings per share
computation |            |                              | (5,988,693 | )                          |            |            | (3,710,347 | )          |             |             | (10,237,551 | )          |          |          | (955,697 | )
|Effect of dilutive securities:                                                        |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |         
|                                                                                      | Stock options, warrants and
convertible preferred stock                 |                                                                                         |                                                                                       |           |                              |            |                            |           |            |            |            |            |             |             |            |         |         
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |          |         
|                                                                                      |                                                                         | Net loss attributable to common
shareholders for diluted
earnings per share computation |                                                                                       | $          | (5,988,693                   | )          |                            | $          | (3,710,347 | )          |            | $           | (10,237,551 | )           |            | $        | (955,697 | )       
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |          |         
|Denominator:                                                                          |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |         
|Shares for basic and diluted net
loss per share  weighted average
shares outstanding |                                                                         |                                                                                         | 58,352,406                                                                            |            |                              |            | 58,240,466                 |            |            |            | 58,324,174 |             |             |             | 58,133,775 |         
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |          |         
|Basic and diluted net loss per share                                                  |                                                                         | $                                                                                       | (0.10                                                                                 | )          |                              | $          | (0.06                      | )          |            | $          | (0.18      | )           |             | $           | (0.02      | )       
|                                                                                      |                                                                         |                                                                                         |                                                                                       |            |                              |            |                            |            |            |            |            |             |             |             |            |         

For the three months ended March 31, 2003 and 2002, options to purchase
6,450,676 and 5,617,342 shares of common stock, respectively, were excluded
from the computation of diluted net loss per share, as the inclusion of such
shares would be antidilutive. For the six months ended March 31, 2003 and
2002, options to purchase 6,450,676 and 5,617,342 shares of common stock,
respectively, were excluded from the computation of diluted net loss per share,
as the inclusion of such shares would be antidilutive.

For the three months ended March 31, 2003 and 2002, warrants to purchase
1,031,350 and 1,184,550 shares of common stock were excluded from the
computation of diluted net loss per share, as the inclusion of such shares
would be antidilutive. For the six months ended March 31, 2003 and 2002,
warrants to purchase 1,031,350 and 1,184,550, shares of common stock,
respectively, were excluded from the computation of diluted net loss per share,
as the inclusion of such shares would be antidilutive.

13



---



##### Table of Contents



For the three months ended March 31, 2003 and 2002, preferred stock convertible
into 577,073 and 218,646 shares of common stock, respectively, were excluded
from the computation of diluted net loss per share, as the inclusion of such
shares would be anti-dilutive. For the six months ended March 31, 2003 and
2002, preferred stock convertible into 577,073 and 218,646 shares of common
stock, respectively, were excluded from the computation of diluted net loss per
share, as the inclusion of such shares would be antidilutive.



|11. |  | SHAREHOLDERS EQUITY
|--- |  | --------------------

Preferred Stock

Preferred stock consists of Series C Junior Participating Preferred Stock and
Series D Redeemable Convertible Preferred Stock.

Series C Junior Participating Preferred Stock.None of the Series C Junior
Participating Preferred Stock is outstanding.

Series D Redeemable Convertible Preferred Stock.As of March 31, 2003 and
September 30, 2002, 50 shares of Series D redeemable convertible preferred
stock (Series D Shares) remained outstanding in connection with a securities
purchase agreement made with certain investors on March 22, 1999. The Series
D holders may convert any or all of the remaining Series D Shares into shares
of Class A common stock at a conversion rate equal to $10,000 divided by a
conversion price equal to the lesser of:



| |  | the Fixed Conversion Price an amount equal to $2.715 per share of Class A common stock; or                                    
|- |  | -------------------------------------------------------------------------------------------------------------------------------
| 
| |  | the Variable Conversion Price an amount equal to 86% of the market price of our Class A common stock, defined as the
lower of:



| | - |  | the average of the five lowest trading prices per share of Class A
common stock on The American Stock Exchange during the 25 trading days
immediately preceding a given date of determination, where trading
price is determined as the average of the high and low trading prices
of our Class A common stock on a particular trading day; or
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | - |  | the average of the high and low trading price per share of Class A
common stock on The American Stock Exchange on the date of
determination.                                                                                                                                                                                                  

Class A Common Stock

On February 11, 2003, the holder of Class K Warrants exercised its right to
purchase 53,200 shares of Class A common stock at an exercise price of $1.125
per share, for cash in the aggregate amount of $59,850.

On March 13, 2003, we amended our 2000 Stock Option Plan to allow for the
issuance of restricted stock awards. Also on that date, we awarded to each non-employee director 10,000 shares
of restricted Class A common stock. The shares awarded to each director are held in escrow by the Secretary of
the Company and will be released from escrow upon his or her termination of service as a director of the Company.
The value of the Class A common stock on the date of grant was $1.16 per share and we recorded compensation
expense in the amount of $92,800 in connection with these awards.

On March 13, 2003, the board of directors approved the adoption of a 2003
equity incentive plan (the 2003 Equity Incentive Plan) that provides for the
issuance of up to 2,500,000 shares of Class A

14



---



##### Table of Contents



common stock. The 2003 Equity Incentive Plan allows us to grant options,
restricted stock awards and stock appreciation rights to our directors,
officers, employees and consultants. As of March 31, 2003, 2,500,000 shares of
Class A common stock remained available for issuance under the 2003 Equity
Incentive Plan.



|12. |  | RECENT ACCOUNTING PRONOUNCEMENTS
|--- |  | --------------------------------

In July 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated
with Exit or Disposal Activities, which addresses financial accounting and
reporting for costs associated with exit or disposal activities and supersedes
EITF Issue 94-3, Liability Recognition for Certain Employee Termination
Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred
in a Restructuring). SFAS No. 146 requires that a liability for a cost
associated with an exit or disposal activity be recognized when the liability
is incurred. Under Issue 94-3, a liability for an exit cost as defined in EITF
94-3 was recognized at the date of an entitys commitment to an exit plan. SFAS
No. 146 also establishes that the liability should initially be measured and
recorded at fair value. SFAS No. 146 became effective for the Company on
January 1, 2003. The application of SFAS No. 146 did not have a material
impact on the Companys financial statements.

In November 2002, the FASB issued FASB Interpretation No. 45, Guarantors
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others, which elaborates on the disclosures to
be made by a guarantor about its obligation under certain guarantees issued.
It also clarifies that a guarantor is required to recognize, at the inception
of a guarantee, a liability for the fair value of the obligation undertaken in
issuing the guarantee. The Interpretation expands on the accounting guidance
of SFAS No. 5, Accounting for Contingencies, SFAS No. 57, Related Party
Disclosures, and SFAS No. 107, Disclosures about Fair Value of Financial
Instruments. It also incorporates without change the provisions of FASB
Interpretation No. 34, Disclosure of Indirect Guarantees of Indebtedness of
Others. FASB Interpretation No. 45 became effective for the Company on
January 1, 2003. The application of FASB Interpretation No. 45 did not have a
material impact on the Companys financial statements.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based
Compensation  Transition and Disclosure, an Amendment of FASB Statement No.
123. SFAS No. 148 provides alternative methods of transition for a voluntary
change to the fair value-based method of accounting for stock-based employee
compensation. In addition, SFAS No. 148 amends the disclosure requirements of
SFAS No. 123 to require prominent disclosures in both annual and interim
financial statements about the method of accounting for stock-based
compensation and the effect of the method used on reported results. The
voluntary transition and amended disclosure requirements are effective for the
Company for the fiscal year ending September 30, 2003. The interim reporting
requirements became effective for the Companys interim periods beginning
January 1, 2003. The Company currently accounts for stock-based employee
compensation under the intrinsic value method in accordance with APB No. 25.
The Company does not plan to voluntarily change its method of accounting, but
has implemented the amended disclosure requirements for the quarter ended March
31, 2003.

In January 2003, the FASB issued FASB Interpretation No. 46, Consolidation of
Variable Interest Entities, an Interpretation of ARB No. 51. Interpretation
No. 46 provides guidance for identifying a controlling financial interest
established by means other than voting interests. It requires consolidation of
a variable interest entity by an enterprise that holds such a controlling
financial interest. The Interpretation is effective for all newly formed
variable interest entities after January 31, 2003. The Interpretation is
effective for fiscal years or interim periods beginning after June 15, 2003 for
variable interest entities in which a company holds a variable interest that it
acquired before February 1, 2003. The adoption of FASB Interpretation No. 46
did not have a material impact on the Companys financial statements.

15



---



##### Table of Contents








|13. |  | CONTINGENCIES
|--- |  | -------------

In the ordinary course of business, we may face various claims brought by third
parties, including claims relating to the safety or efficacy of our products.
Any of these claims could subject us to costly litigation and, while we
generally believe that we have adequate insurance to cover many different types
of liabilities, our insurance carriers may deny coverage or our policy limits
may be inadequate to fully satisfy any damage awards or settlements. If this
were to happen, the payment of any such awards could have a material adverse
effect on our operations and financial position. Additionally, any such claims,
whether or not successful, could damage our reputation and business. Management
believes the outcome of currently identified claims and lawsuits will not have
a material adverse effect on the Companys operations or financial position.



|14. |  | SUBSEQUENT EVENT
|--- |  | ----------------

On April 29, 2003, AVANIR received $3.6 million from Drug Royalty USA upon
AVANIR receiving a certificate of extension of U.S. Patent Number 4,874,794
that extended the expiration date of a key docosanol (Abreva®) patent from
April 2009 to April 2014. In December 2002, AVANIR sold an undivided interest
in its Abreva license agreement with GlaxoSmithKline to Drug Royalty USA for
$24.1 million and received an initial payment of $20.5 million. (See Note 7, "Asset Sale.")
The balance of the contract amount, $3.6 million, was due upon the grant by the U.S. Patent
and Trademark Office of the patent term extension. We classified the
additional amount received as deferred revenue, to be recognized ratably over
the life of the license agreement.

Item 2.    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements
concerning future events and performance of our company. You should not rely
excessively on these forward-looking statements, because they are only
predictions based on our current expectations and assumptions. When used in
this report, the words intend, estimate, anticipate, believe, plan or
expect and similar expressions are included to identify forward-looking
statements. Many factors could cause our actual results to differ materially
from those indicated in these forward-looking statements. You should review
carefully the factors identified in this report as set forth below and under
Risk Factors that Might Affect Future Results and in our most recent Annual
Report on Form 10-K filed with the Securities and Exchange Commission (SEC).
We disclaim any obligation or intent to update or announce revisions to any
forward-looking statements to reflect actual events or developments.

Overview

AVANIR Pharmaceuticals, based in San Diego and incorporated in California in
1988, is a drug discovery and development company with a commercialized
FDA-approved product (Abreva®) and products in clinical development for the
treatment of pseudobulbar affect (Phase III), neuropathic pain (Phase II), and
allergy and asthma (Phase I). AVANIR is engaged in small-molecule research to
development treatments for central nervous system disorders and inflammatory
diseases. Through the use of its Xenerex technology, AVANIR also develops
human monoclonal antibodies for infectious diseases and other therapeutic
applications.

AVANIRs first commercialized product, docosanol 10% cream, is a topical
treatment for cold sores. The product is also known as Abreva in the United
States and Canada, Herepair in South Korea and Abrax in Israel and is being
marketed in those countries. A regulatory decision on marketing approval of
the product in Sweden is pending. AVANIR has out-licensed docosanol 10% cream
in the United States and in several foreign countries. AVANIR is continuing to
expand its commercialization efforts for docosanol

16



---



##### Table of Contents



10% cream while pursuing a broader effort to discover new drugs and develop
others that are already in our development pipeline.

AVANIRs offices and research facilities are located at 11388 Sorrento Valley
Road, Suite 200, San Diego, California 92121. Our telephone number is (858)
622-5200 and our e-mail address is info@AVANIR.com.Additional information
about AVANIR can be found on our website, at www.AVANIR.com,and in our
periodic and current reports filed with the SEC. Copies of our current and
periodic reports filed with the SEC are available at the SEC Public Reference
Room at 450 Fifth Street, N.W., Washington, D.C. 20549, and online at
www.sec.govand our website at www. AVANIR.com.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements in accordance with accounting
principles generally accepted in the United States requires that management
make a number of assumptions and estimates that affect the reported amounts of
assets, liabilities, revenues and expenses in our consolidated financial
statements and accompanying notes. Management bases its estimates on
historical information and assumptions believed to be reasonable. Although
these estimates are based on managements best knowledge of current events and
actions that may impact the Company in the future, actual results may differ
from these estimates and assumptions.

Our critical accounting policies are those that affect our financial statements
materially and involve a significant level of judgment by management. Our
critical accounting policies regarding revenue recognition are in the following
areas: milestone payments in license agreements, royalties on licensed products,
sale of rights to future royalties and recognition of revenues in research contracts. Our critical
accounting policies regarding expense recognition are principally related to
research contracts.

Milestone Payments in License Agreements

We recognize revenues from license fees when the performance requirements have
been met, the fee is fixed or determinable, and collection of fees is probable.
We defer revenues and recognize them ratably over the life of the agreement
when we have continuing obligations to perform under the agreement.

Our largest and most significant license agreement is with SB Pharmco Puerto
Rico, Inc., a subsidiary of GlaxoSmithKline (GlaxoSmithKline). On March 31,
2000, we transferred the rights to manufacture, use, and sell Abreva in the
United States and Canada to GlaxoSmithKline and gave them full control,
authority and responsibility over research, development, registration including
actions required to obtain appropriate government approvals, and
commercialization of the product in that territory. GlaxoSmithKline has
achieved and paid all of the performance milestones under the agreement. With
regard to the milestones, we have no further performance obligations. Future
revenues, if any, to be earned under the GlaxoSmithKline agreement will come
solely from royalty revenues.

We expect to enter into additional license agreements in the future. We expect
that each license agreement will have its own set of circumstances and terms of
performance. We will consider the specific facts and circumstances of each
license agreement to determine the appropriate revenue recognition for such
items, including nonrefundable up-front fees and milestone payments and taking
into consideration when the earnings process is complete and collection is
reasonably assured.

Royalties on Licensed Products

We recognize royalty revenues from our licensed products based on the reported
sales by our licensees and computed in accordance with the specific terms of
the license agreements. Since the launch of Abreva in October 2000 through
March 31, 2003, substantially all of our royalties have come from
GlaxoSmithKline. We have entered into additional license agreements that
contain royalties as a source

17



---



##### Table of Contents



of revenues, and we expect to enter into additional similar license agreements
with foreign-based companies.

Sale of Rights to Future Abreva Royalties

In December 2002, we sold an undivided interest in our license agreement with
SB Pharmco Puerto Rico, Inc. (SB or GlaxoSmithKline) to Drug Royalty USA,
Inc. (Drug Royalty USA) and received an initial payment of $20.5 million.
Because of our ongoing involvement with GlaxoSmithKline in earning future
royalty revenues, we have recorded the amount received from Drug Royalty USA,
net of costs of the transaction and after the forgiveness of certain advances,
as deferred revenue. (See Note 7, Asset Sale, and Note 14, Subsequent
Event, in the accompanying financial statements.) The amount recorded as
deferred revenue is being recognized as revenue under the units-of-revenue
method. Under this method, the amount of deferred revenue being recognized as
revenue in each period is calculated by multiplying (i) the ratio of the
royalty payments due to Drug Royalty USA for the period to the total remaining
royalties that we expect SB will pay Drug Royalty USA over the term of the
agreement, by (ii) the unamortized deferred revenue amount. The portion of
deferred revenue classified as part of current liabilities represents the
amount AVANIR expects to realize as revenue within the next 12 months.

Recognition of Revenues in Research Contracts

In certain circumstances, we may enter into research contracts or
collaborations having obligations to deliver to the customer multiple products
and/or services (multiple deliverables) in exchange for fees or milestone
payments. Such contracts could include antibody generation services agreements
and other forms of research collaborations.

Antibody generation services. As of March 31, 2003, Xenerex Biosciences, our subsidiary, was engaged in work
on two research collaboration agreements, both of which have research
initiation fees. In these agreements, the customer provides antigens to
Xenerex. Xenerex then performs research to develop potential antibodies for
those antigens. We defer research initiation fees and recognize such fees as
revenue once Xenerex has completed its efforts to create antibodies. In the
research phases of the research collaboration agreement, Xenerex may receive
payment either to start a research phase or to complete a research phase
(including receipt by the customer of the deliverable). We recognize revenue
once the product has been delivered, because the earning process would be
complete and an exchange has been made. Factors taken into consideration in
recognizing revenues include the following:



| |  | The performance criteria have been met;                                                                                              
|- |  | -------------------------------------------------------------------------------------------------------------------------------------
| 
| |  | Any undelivered products or services are not essential to the
functionality of the delivered products or services;                   
| 
| |  | Payment for the delivered products or services is not contingent on
delivery of the remaining products or services; and              
| 
| |  | We have an enforceable claim to receive the amount due in the event we
do not deliver the remaining undelivered products or services.

Other research contracts.As with all our research contracts, including the
up-front initiation fee, we defer revenue recognition until services have been
rendered or products (e.g. developed antibodies) are delivered. The milestones
established within the contract are set to approximate the effort associated
with the completion of each phase. Regardless of when we receive the payment
associated with a research phase, we defer the revenue recognition until the
service is completed or product is delivered.

18



---



##### Table of Contents



Recognition of Expenses in Research Contracts

The Company recognizes expenses related to its clinical trials and other
research contracts as the services are provided.

RESULTS OF OPERATIONS 

Comparison of Three Months Ended March 31, 2003 and 2002

Revenues

Revenues in the second quarter of fiscal 2003 amounted to $622,000, compared to
$738,000 for the same period last year. Revenues in the second quarter of
fiscal 2003 included $480,000 in revenues that the Company recognized from the
sale of Abreva® royalty rights to Drug Royalty USA and $140,000 from government
research grants. In December 2002, Avanir sold rights to a portion of Abreva
royalties to Drug Royalty USA and received $20.5 million at the closing.
Avanir is recognizing the payment as revenue over the term of the agreement
with Drug Royalty USA, or until April 2014. (See Note 7, Asset Sale.)
Revenues in the second quarter of fiscal 2002 included $720,000 in royalties on
Abreva product sales.

During fiscal 2003, we expect to recognize approximately $2.0 million in
revenues from the sale transaction to Drug Royalty USA, with a corresponding
reduction in deferred revenue. Also during the fiscal year, we expect to earn
approximately $600,000 in revenues from research being performed under
government research grants. Potential revenues from license fees, milestone
payments, and royalties on foreign sales of docosanol 10% cream will depend
substantially on the timing of approval decisions by foreign regulatory
agencies and our ability to enter into additional license arrangements and
achieve milestones under those arrangements. Potential revenues from licensing
and/or selling products in clinical and preclinical development, including
Neurodex and treatments for inflammatory diseases and high cholesterol, are
less predictable.

Revenue-generating Contracts

Partnering, licensing and research collaborations have been, and will continue
to be, an important part of AVANIRs business development strategy. We intend
to partner with pharmaceutical companies that can help fund AVANIRs research
in exchange for sharing in the rights to commercialize new drugs coming from
this research. We have licensed and continue to seek licensees in other
countries for docosanol 10% cream and other potential products in our
development pipeline. Research collaborations also represent an important way
to achieve our development goals, while sharing in the risks and the
opportunities that come from such development efforts.

As of May 1, 2003, we had eight commercial contracts, one license purchase
agreement, and five government-funded research grants that are generating or
could generate revenues in the future to help fund our research and development
programs. Five of the commercial contracts are in the form of docosanol 10%
cream (Abreva) license agreements, one contract is for a Neurodex license, and
two contracts are through Xenerex and are in the form of antibody research
service agreements. For the last three years, GlaxoSmithKline has been our
most significant revenue source, representing over 95% of the Companys
revenues in fiscal 2002. A list of our revenue-generating contracts is set
forth in the following table.

19



---



##### Table of Contents



|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|---------------------------------------------------------------------------------------------------------------- |  | ---------------------------------------------------------------------------------------------------------------- |  | --------------------------------- |  | --------------------------------------------------------------------
|Revenue-generating Contracts                                                                                    
|                                                                                                                
|                                                                                                                 |  | Type of Agreement                                                                                                |  | Date of Agreement                 |  | Product License, Sale,                                              
|Company or Research Grant                                                                                        |  | or Grant Award                                                                                                   |  | or Grant Award                    |  | Service or Research                                                 
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|GlaxoSmithKline                                                                                                  |  | Undivided interest in the
license agreement for
Abreva®
(U.S. and Canada)                                        |  | March 31, 2000                    |  | Cold sore product license                                           
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|Drug Royalty USA                                                                                                 |  | License Purchase Agreement,
representing an undivided
interest in the Abreva
license agreement (U.S.
and Canada) |  | November 22, 2002                 |  | Sale of undivided
interest in Abreva
license agreement and
royalties
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|CTS Chemical Industries, LTD                                                                                     |  | Docosanol license (known
as Abrax in Israel)                                                                     |  | July 6, 1993                      |  | Cold sore product license                                           
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|Boryung Pharmaceuticals Co., LTD                                                                                 |  | Docosanol license (known
as Herepair in South
Korea)                                                             |  | March 11, 1994                    |  | Cold sore product license                                           
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|BioPharm Group                                                                                                   |  | Docosanol license
(Egypt)                                                                                        |  | January 11, 2002                  |  | Cold sore product license                                           
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|Bruno Farmaceutici S.p.A                                                                                         |  | Docosanol license
(Italy)                                                                                        |  | July 29, 2002                     |  | Cold sore product license                                           
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|Medison Pharma, Ltd.                                                                                             |  | Neurodex license
(Israel)                                                                                        |  | August 6, 2002                    |  | Pseudobulbar Affect
research and
commercialization
agreement        
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|Peregrine Pharmaceuticals                                                                                        |  | Antibody research                                                                                                |  | June 7, 2001                      |  | Antibody generation
services                                        
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|DNAX Research, Inc.                                                                                              |  | Antibody research                                                                                                |  | January 21, 2002                  |  | Antibody generation
services                                        
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|Small Business Innovative
Research (SBIR) Grant Program
and California Technology
Investment Partnership Program |  | Two government research
grants (Federal and State)                                                               |  | March 12, 2002 and
April 26, 2002 |  | Pre-clinical research of
potential genital herpes
product           
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|California Center for Advanced
Technology (CCAT)                                                                 |  | Two Department of Defense
grants administered
through San Diego State
University Foundation                      |  | June 19, 2002 and
March 20, 2003  |  | Pre-clinical anthrax
antibody research and
blood donor program      
|                                                                                                                 |  |                                                                                                                  |  |                                   |  |                                                                     
|National Institutes of Health;
Phase I SBIR                                                                      |  | Federal research grant                                                                                           |  | April 25, 2003                    |  | Human antibodies to
cytomegalovirus (CMV)                           

20



---



##### Table of Contents



Expenses

Operating Expenses.Total operating expenses were $6.7 million in the second
fiscal quarter 2003, compared to $4.6 million in the same period in fiscal
2002. The 45% increase in operating expenses was primarily caused by a 54%
increase in spending on research and development programs. Research and
development programs accounted for 73% and 69% of total operating expenses for
the fiscal quarters ended March 31, 2003 and 2002, respectively. General and
administrative expenses accounted for 18% and 23% of total operating expenses
for the fiscal quarters ended March 31, 2003 and 2002, respectively. Sales and
marketing expenses accounted for 9% and 8% of total operating expenses for the
fiscal quarters ended March 31, 2003 and 2002, respectively. These and other
costs are more fully described below.

Research and Development Expenses.Research and development (R&D) expenses
were $4.9 million in the second fiscal quarter 2003, compared to $3.2 million
in the same period a year ago. Avanir had four clinical trials under way in
the second quarter of fiscal 2003, compared to one clinical trial during the
same period a year ago. Also during the quarter ended March 31, 2003, the
Company entered into 16 additional contracts totaling $1.5 million for research
services related to the development of Neurodex. The effect of these contracts
and other recent new contracts accounts for the increase in prepaid expenses at
March 31, 2003. We expect that these prepaid expenses will be recognized as
expenses during the coming six to twelve months as the services are performed.

During the second fiscal quarter 2003, the Phase III clinical trials for
Neurodex in the treatment of pseudobulbar affect (PBA) in patients with
multiple sclerosis and the open-label study of Neurodex in the treatment of PBA in
patients with neurological disorders accounted for 44% of all R&D spending.
The Phase III clinical trial program for Neurodex had reached approximately 15%
of completion as of March 31, 2003. Costs associated with the Companys
allergy and asthma research program accounted for 26% of total R&D spending,
representing costs of preparing an application for Investigational
New Drug (IND)
status with the FDA, preparation of clinical supplies, and initiating Phase I
clinical trials of AVANIRs lead compound. Avanir has also been conducting
research related to discovery of a second-generation allergy and asthma
compound. The balance of R&D spending was for other programs, including
pre-clinical research related to inflammation and cholesterol-lowering
compounds and an antibody to the anthrax toxin, and other antibody research
programs.

In the second fiscal quarter 2002, R&D expenses were primarily related to
pre-clinical development of an orally-bioavailable compound for the treatment
of allergy and asthma, a Phase II/III clinical trial for Neurodex in treating
pseudobulbar affect, and development of the antibody generation technology.

We expect to continue efforts on three clinical development programs 
treatments for pseudobulbar affect (Phase III trial and open-label study),
neuropathic pain (Phase II) and allergy and asthma (Phase I)  and earlier
stage research in the areas of inflammation, cholesterol reduction and
infectious diseases.

We caution that many of our R&D efforts could experience delays, setbacks and
failures, with no assurance that any of our clinical research or
research conducted by our
licensees or partners will ever reach the stage of a new drug application (NDA)
with the FDA or that the NDA will be approved. The following table sets forth
the status of, and costs attributable to, our proprietary research and clinical
development programs.

21



---



##### Table of Contents



|                                                                                                                                                                                                                                                                                               |       |          |                    |           |                  |          |           |           |           |             |           |             |  |   |           |           |  |   |            |            |             |   |       |     | 
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- | -------- | ------------------ | --------- | ---------------- | -------- | --------- | --------- | --------- | ----------- | --------- | ----------- |  | - | --------- | --------- |  | - | ---------- | ---------- | ----------- | - | ----- | --- | 
|Research and Development Projects and Other Research Programs Expense                                                                                                                                                                                                                          |       |         
|                                                                                                                                                                                                                                                                                              
|                                                                                                                                                                                                                                                                                               |       |          | Three Months Ended |           | Six Months Ended |          |           |           |          
|                                                                                                                                                                                                                                                                                               |       |          | March 31,          |           | March 31,        |          | Inception |           | Estimated
|                                                                                                                                                                                                                                                                                               |       |          |                    |           |                  |          | Through   |           | Cost     
|                                                                                                                                                                                                                                                                                               |       |          |                    |           |                  |          |           |           |           |             |           |             |  |   |           |           |  |   | March 31,  |            | To Complete
|Company-Funded Projects (1):                                                                                                                                                                                                                                                                   |       | 2003 (2) |                    | 2002 (2)  |                  | 2003 (2) |           | 2002 (2)  |           | 2003(2) (3) |           | Project (2)
|                                                                                                                                                                                                                                                                                               |       |          |                    |           |                  |          |           |           |           |             |           |            
|Development of Neurodex for
FDA marketing approval in
treating PBA. Estimated
timing to complete
remaining phases of project
necessary to file a New
Drug Application with the
FDA is mid- 2004                                                                                                |       | $        | 1,529,437          |           |                  | $        | 756,574   |           |           | $           | 2,103,395 |             |  | $ | 1,286,636 |           |  | $ | 7,476,296  |            |             | $ | 5M    |    
|Development of Neurodex for
neuropathic pain. Estimated
timing to complete Phase
II: second quarter of 2003.
Estimated timing to
license the product: fourth
quarter of 2003                                                                                                                   |       |          | 611,845            |           |                  |          | 307,942   |           |           |             | 710,784   |             |  |   | 579,613   |           |  |   | 3,346,910  |            |             |   | 2M    |    
|Develop AVP-13358 as a
treatment for allergy and
asthma. Estimated timing
to complete Phase I and
bioanalytical work: third
quarter of 2004; Estimated
timing to license the
product: first quarter of
2005                                                                                    |       |          | 1,247,157          |           |                  |          | 825,453   |           |           |             | 2,483,614 |             |  |   | 1,407,908 |           |  |   | 12,316,788 |            |             |   | 4-5M  |    
|Develop compound for
regulating the target, MIF,
as a potential treatment
for inflammatory diseases.
Estimated timing to
complete development
through Phase I: third
quarter of 2005. Estimated
timing to license the
product: fourth quarter of
2005                                          |       |          | 391,256            |           |                  |          | 570,763   |           |           |             | 1,017,831 |             |  |   | 830,112   |           |  |   | 3,845,868  |            |             |   | 8-10M |    
|Government-Funded Projects:                                                                                                                                                                                                                                                                    |       |          |                    |           |                  |          |           |           |           |             |           |             |  |   |           |           |  |   |            |            |             |   |       |    
|Pre-clinical research for
potential treatments for
genital herpes and anthrax
and development of a blood
donor program for
infectious diseases.
Estimated timing to
complete the various
projects is up to one year                                                                            |       |          | 177,276            |           |                  |          | 1,298     |           |           |             | 346,031   |             |  |   | 1,320     |           |  |   | 645,874    |            |             |   | 0.7M  | (4)
|Other Pre-clinical Research
Projects:                                                                                                                                                                                                                                                          |       |          |                    |           |                  |          |           |           |           |             |           |             |  |   |           |           |  |   |            |            |             |   |       |    
|Use of proprietary
technologies (CCM and
antibody generation
technology) to pursue
potential treatments for
lowering cholesterol and
treating infectious
diseases. Costs and timing
to complete pre-clinical
research are unpredictable
because of the uncertainty
of outcomes of the research |       |          | 903,308            |           |                  |          | 702,878   |           |           |             | 1,810,246 |             |  |   | 1,406,178 |           |  |   | 11,432,109 |            |             |   |      |    
|                                                                                                                                                                                                                                                                                               |       |          |                    |           |                  |          |           |           |           |             |           |             |  |   |           |           |  |   |            |            |             |   |       |    
|                                                                                                                                                                                                                                                                                               | Total |          | $                  | 4,860,280 |                  |          | $         | 3,164,908 |           |             | $         | 8,471,902   |  |   | $         | 5,511,767 |  |   | $          | 39,063,845 |             |   |       |     | 
|                                                                                                                                                                                                                                                                                               |       |          |                    |           |                  |          |           |           |           |             |           |             |  |   |           |           |  |   |            |            |             |   |       |    



|1. |  | At March 31, 2003, we held the worldwide rights to manufacture,
market and sell all of the products in clinical development and any of
the products that might come from our own internal R&D programs. All
dates in the schedule refer to calendar year.
|-- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|  
|2. |  | Each project includes allocation of laboratory occupancy costs. M
refers to millions.                                                                                                                                                                  
|  
|3. |  | Inception dates are on or after October 1, 1998, at which time we
began identifying and tracking costs for these research programs.                                                                                                                      
|  
|4. |  | State and Federal research grants totaling $1.4 million are related
to genital herpes, antibodies to anthrax and cytomegalovirus, and a blood
donor program.                                                                                             

22



---



##### Table of Contents



Research and Development Program Strategy

We are pursuing an R&D program strategy that is intended to provide a stream of
potential products in various stages of development as well as in several
therapeutic areas and technology platforms. Our approach is not to rely on any
one therapeutic area or technology platform, but to extend our development
expertise across several therapeutic areas, technology platforms and research
targets that could lead to a product. To help conserve cash resources as we
continue these R&D programs, we intend to use our own funds for clinical trials
that are relatively small and license our products and technologies to others
when we expect the development costs will exceed available cash resources. We
are pursuing this strategy because the costs of pursuing all of our development
programs through all clinical phases are beyond our current available cash
resources. There can be no assurances that we will be successful in licensing
any of our products or technologies.

Neurodex for the treatment of PBA.We completed the initial Phase II/III
clinical trial in May 2002. We intend to use the trial to qualify as one of
two required pivotal clinical trials necessary to obtain FDA approval for
marketing the product in the United States. A second Phase III clinical trial
and an open label study are currently underway. Our goal is to complete the
enrollments in the Phase III trial before the end of calendar year 2003. If the
Phase III trial is successful, we intend to file a New Drug Application (NDA) with the
FDA by mid-2004 calendar year. If we are successful in filing an NDA, then we
expect to develop our own sales force in preparation for selling the product if
it is approved by the FDA. We also intend to find a licensee and/or
co-promotion partner for Neurodex for both indications of PBA and neuropathic
pain, as more fully described below.

Neurodex for the treatment of neuropathic pain.Our Phase II open-label study
of escalating doses of Neurodex in the treatment of neuropathic pain is an
important clinical development stage that should provide significant
information to potential licensees or co-promotion partners. Following
completion of the Phase II studies, we intend to seek a licensee of Neurodex
for all markets outside the United States and a co-promotion partner to share
in the distribution of the product in the United States. We expect to complete
the Phase II studies and report the results by June 30, 2003. Assuming the
results are favorable, we expect to find a licensee and/or co-promotion partner
by December 31, 2003, and begin recognizing revenues after licensing the
product.

Development program for allergy and asthma (IgE regulator).In March 2003, we
initiated Phase Ia clinical trials of our lead oral compound for the treatment
of allergy and asthma. Our compound appears capable of selectively inhibiting
the production of immunoglobulin epsilon (IgE) antibodies, a target that has
been identified in the pathophysiology of allergy and asthma. Phase 1a trials
are intended to establish safety of the drug in single rising doses in healthy
patients and to assess the compounds affect on certain disease biomarkers.
These trials will be followed by Phase Ib clinical trials using rising
multi-doses in healthy patients. We estimate that Phase Ib clinical trials for
this compound will be completed by mid-2004 calendar year. Assuming the
results are favorable, we expect to license the drug to another pharmaceutical
company and begin recognizing revenues from our partner by mid-2005 calendar
year. Also during fiscal 2003 and 2004 we expect to pursue development of a
second-generation compound.

Anti-inflammatory research program (MIF inhibitor).We are currently
conducting toxicology studies and other preclinical research on several
potential drug candidates capable of inhibiting or blocking the activity of
macrophage migration inhibitory factor (MIF). Our research indicates that MIF
may serve as a potential drug target in a variety of diseases, including
rheumatoid arthritis, Crohns disease, colitis and asthma. Assuming we are
successful in finding a lead compound and filing for an IND, we would expect to
complete Phase I clinical trials to establish safety in humans by mid-2005
calendar year. By December 2005, we intend to license the compound to another
pharmaceutical company and begin recognizing positive cash flows thereafter
from our partner.

23



---



##### Table of Contents



Government research contracts.AVANIR also is engaged in research funded by
$1.4 million in government research grants. The government research grants are
to be used for investigating the market potential for a topical genital herpes
treatment, conducting research on various docosanol-based formulations for a
potential genital herpes product, development of antibodies to anthrax toxins
and cytomegalovirus, and development of a blood donor program intended to find
high-affinity antibodies to infectious diseases. We expect the current
government-funded research programs will continue through fiscal years 2003 and
part of fiscal 2004.

Other Operating Expenses

General and Administrative Expenses.During the second fiscal quarter 2003,
general and administrative expenses amounted to $1.2 million, slightly higher
than the second fiscal quarter 2002. The Company continues to concentrate its
efforts on R&D programs and market research for Neurodex and expects that
near-term increases in general and administrative expenses will be moderate.

Sales and Marketing Expenses.During the second fiscal quarter 2003, sales and
marketing expenses were $606,000, compared to $361,000 in the same period a
year ago. Higher expenses in the second fiscal quarter 2003 were related to
market research and planning and preparation for product launch of Neurodex for
the treatment of pseudobulbar affect. Sales and marketing activity for the
same period in fiscal year 2002 was directed toward licensing of docosanol 10%
cream in overseas markets.

Loss from Operations

For the second fiscal quarter 2003, the loss from operations was $6.1
million, compared to $3.9 million for the same period a year ago.
Contributing to the higher losses were the higher R&D expenses associated with
additional clinical development programs and costs related to product planning
for Neurodex. Revenues decreased by 16%, reflecting the sale of rights to a
portion of future Abreva royalties. Higher operating expenses reflected the
greater number and extent of R&D programs and increases in sales and marketing
activities, including market research and planning for the product launch of
Neurodex in the treatment of PBA.

Other Income and Expenses

Interest Income.In the second fiscal quarter 2003, interest income amounted
to $85,000, compared to $181,000 for the same period a year ago. The decrease
in interest income during the second fiscal quarter 2003 was primarily due to
lower interest rates on investments and lower average invested amounts compared
with the same period a year ago.

Other Income.Other income, consisting of rental income, was $6,000 in the
second quarter of fiscal 2003, compared to $4,000 in the same period a year
ago.

Interest Expense.In the second fiscal quarter 2003, interest expense amounted
to $13,000, compared to $18,000 for the same period a year ago. Lower interest
expense for the second fiscal quarter 2003 was due to lower interest rates on
extended payment plans for our insurance policies.

Net Loss

For the second fiscal quarter 2003, the net loss attributable to common
shareholders was $6.0 million, compared to $3.7 million for the same period a
year ago. The basic and diluted net loss per share was $0.10 for the second
fiscal quarter 2003, compared to $0.06 for the same period a year ago.

24



---



##### Table of Contents



For the remainder of the 2003 fiscal year, we expect to continue developing our
current products, with particular emphasis on products engaged in clinical
trials. We intend to continue to develop Neurodex for the treatment of both
pseudobulbar affect (PBA) (Phase III status) and neuropathic pain (Phase II
status) and our lead compound for the treatment of allergy and asthma (Phase I
status). We expect that our spending on clinical trials and earlier stage R&D
programs, combined with other operating costs, will exceed our revenues for at
least the next two quarters. We anticipate that we will file a New Drug
Application with the FDA in the first half of calendar year 2004 for Neurodex
for the treatment of PBA.

RESULTS OF OPERATIONS 

Comparison of Six Months Ended March 31, 2003 and 2002

Revenues

Revenues for the first six months of fiscal 2003 amounted to $1.4 million,
compared to $6.9 million for the same period last year. Revenues for the first
six months of fiscal year 2003 included $1.1 million in revenues that the
Company recognized from the sale of certain rights to future Abreva royalties
to Drug Royalty USA, $299,000 from government research grants and $17,000 in
sales of the raw material docosanol. Revenues for the first six months of
fiscal 2003 included a $5 million milestone payment from GlaxoSmithKline and
$1.8 million in royalties on Abreva® product sales.

In recording the sale transaction to Drug Royalty USA, AVANIR increased cash by
$20.4 million (net of transaction costs), reduced accrued expenses by $301,000
in connection with the forgiveness of a related advance, and recorded deferred
revenue in the amount of $20.7 million. We will be recognizing the amount
received from Drug Royalty USA as revenues over approximately a twelve-year
period of the royalty rights sold. (See Note 7, Asset Sale, in the
accompanying financial statements for a detailed description of how the
payments under the agreement with Drug Royalty USA will be recognized.)

Expenses

Operating Expenses.Total operating expenses were $11.8 million in the first
six months of fiscal 2003, compared to $8.2 million in the same period in
fiscal 2002. The 43% increase in operating expenses was primarily caused by a
54% increase in spending on research and development programs. Research and
development programs accounted for 72% and 67% of total operating expenses for
the first six months of fiscal 2003 and 2002, respectively. General and
administrative expenses accounted for 19% and 25% of total operating expenses
for the first six months of fiscal 2003 and 2002, respectively. Sales and
marketing expenses accounted for 9% and 8% of total operating expenses for
first six months of fiscal 2003 and 2002, respectively. These and other costs
are more fully described below.

Research and Development Expenses.Research and development (R&D) expenses
were $8.5 million in the first six months of fiscal 2003, compared to $5.5
million in the same period a year ago. Costs associated with completion of
toxicology, filing an IND and initiating Phase I clinical trials of AVANIRs
lead compound for the treatment of allergies and asthma accounted for 29% of
total R&D spending in the first six months of fiscal 2003. The clinical trials
of Neurodex in the treatment of pseudobulbar affect (PBA) in patients with
multiple sclerosis and in the treatment of neuropathic pain accounted for 33%
of all R&D spending in the first six months of fiscal 2003. The balance of R&D
spending was for other programs, including pre-clinical research related to
inflammation and cholesterol-lowering compounds and antibody research programs.

In the first six months of fiscal 2002, R&D expenses were primarily related to
costs associated with pre-clinical development of an orally-bioavailable
compound for the treatment of allergy and asthma, a Phase

25



---



##### Table of Contents



II/III clinical trial for Neurodex in treating pseudobulbar affect, and
development of the antibody generation technology.

General and Administrative Expenses.General and administrative expenses
amounted to $2.3 million in the first six months of fiscal 2003, representing a
13% increase over expenses of $2.0 million in the same period in the prior
year. Higher expenses were attributable to increased staff size to support
growing R&D programs. General and administrative expenses continued the trend
established in fiscal 2002 of growing at a slower rate than R&D and sales and
marketing expenses.

Sales and Marketing Expenses.During the first six months of fiscal 2003,
sales and marketing expenses were $1.0 million, compared to $681,000 in the
same period a year ago. Higher expenses in the first six months of fiscal 2003
were related to market research and planning and preparation for product launch
of Neurodex for the treatment of pseudobulbar affect. Sales and marketing
activity for the same period in fiscal year 2002 was directed toward licensing
of docosanol 10% cream in overseas markets.

Loss from Operations

For the first six months of fiscal 2003, the loss from operations was $10.4
million, compared to $1.4 million for the same period a year ago.
Contributing to the higher losses were $5.4 million lower revenues, $3.0
million higher R&D expenses, $351,000 higher sales and marketing
expenses and $259,000 higher general and administrative expenses. During the first six
months of fiscal 2003, Avanir did not receive any milestone payments from its
licensees and incurred higher R&D expenses associated with three clinical
development programs and costs related to product planning for Neurodex.
During the first six months of fiscal 2002, Avanir received a $5.0 million
milestone from GlaxoSmithKline and had only one clinical development program
underway.

Other Income and Expenses

Interest Income.In the first six months of fiscal 2003, interest income
amounted to $153,000, compared to $369,000 for the same period a year ago. The
decrease in interest income during the first six months of fiscal 2003 was
primarily due to lower interest rates on investments and lower average invested
amounts compared with the same period a year ago.

Other Income.Other income amounting to $12,000 in the first six months of
fiscal 2003 represents rental income on emergency standby power generating
equipment. Other income, amounting to $87,000 in the first six months of
fiscal 2003, represents miscellaneous Xenerex contract services, rental income
for use of the Companys conference center and rental income on emergency
standby power generating equipment.

Interest Expense.In the first six months of fiscal 2003, interest expense
amounted to $23,000, compared to $33,000 for the same period a year ago. Lower
interest expense for the first six months of fiscal 2003 was due to lower
interest rates on extended payment plans for our insurance policies.

Net Loss

For the first six months of fiscal 2003, the net loss attributable to common
shareholders was $10.2 million, compared to $934,000 for the same period a year
ago. The basic and diluted net loss per share was $0.18 for the first six
months of fiscal 2003, compared to $0.02 for the same period a year ago.

26



---



##### Table of Contents



LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2003, we had cash and cash equivalents of $16.7 million, short
and long-term investments of $2.3 million, restricted investments of
$857,000 and a net working capital balance of $12.0 million, compared to cash
and cash equivalents of $8.6 million, short and long-term
investments of $3.7 million, restricted investments of $857,000 and a net working
capital balance of $5.9 million as of September 30, 2002.

Operating Activities.Net cash provided by operating activities amounted to
$10.8 million in the first six months of fiscal 2003, compared to net cash
provided by operating activities of $215,000 during the same period a year ago.
On December 24, 2002, we sold to Drug Royalty USA an undivided interest in our
Abreva license agreement with GlaxoSmithKline and received $20.4 million, net
of transaction costs. The net cash provided by operating activities in the
first six months of fiscal 2003 reflects the $20.4 million in cash received
from Drug Royalty USA and an $876,000 royalty payment from GlaxoSmithKline,
partially offset by the $10.2 million net loss for the first six months of the
fiscal year. The sale of rights to future Abreva royalties was recorded as
deferred revenue on the date of sale. (See Note 7, Asset Sale in the
accompanying notes to the financial statements.) For the first six months of
fiscal 2002, net cash provided by operations amounting to $215,000 reflected
depreciation and amortization expense ($276,000) and compensation paid with
stock options ($89,000). Other changes in assets and liabilities balances
(e.g. increases in accounts payable and accrued compensation and other accrued
expenses) sufficiently offset the net loss of $934,000 for the first six months
of fiscal 2002.

In April 2003, we received an additional $3.6 million from Drug Royalty USA
upon receiving a certificate of extension of a key Abreva patent from April
2009 to April 2014. (See Note 7, Asset Sale, and Note 14, Subsequent
Event.)

Investing Activities.Net cash used for investing activities during the first
six months of 2003 amounted to $2.6 million, including investments in
securities totaling $706,000, capital expenditures related to construction in
progress on a building expansion ($3.0 million), purchases of property and
equipment ($782,000), and patent costs of $234,000, partially offset by sales
and maturities of investments totaling $2.1 million. Net cash used for
investing activities during the first six months of fiscal 2002 amounted to
$8.0 million, including investments in securities totaling $8.6 million,
capital expenditures for property and equipment totaling $300,000 and patent
costs of $251,000, partially offset by sales and maturities of investments
totaling $1.2 million.

Financing Activities.Net cash used for financing activities amounted to
$207,000 during the first six months of 2003, compared to $45,000 in cash
provided by financing activities for the same period a year ago. We believe
that cash, short and long-term investments in securities and restricted
investments totaling $19.8 million as of March 31, 2003, plus anticipated
future payments and revenues, should be sufficient to sustain our planned level
of operations for at least the next twelve months. Additionally, to continue
to enhance our capital base and liquidity and to continue to fund the
development of our drug candidates and technology platforms, we expect to
continue to pursue various alternatives for raising additional funds during the
next twelve months. Potential alternatives that we are considering for raising
capital include, but are not limited to, partnering arrangements where partners
share development costs, issuance of debt or equity securities, and licensing
or sales of any of our platform technologies or new drug candidates.

RECENT ACCOUNTING PRONOUNCEMENTS

See Note 12, Recent Accounting Pronouncements in the accompanying
financial statements for a discussion of recent accounting pronouncements and
their effect, if any, on the Company.

27



---



##### Table of Contents



RISK FACTORS THAT MIGHT AFFECT FUTURE OPERATIONS

We intend to raise capital over the next twelve months through various
alternatives, including licensing or sales of our platform technologies and new
drug candidates or through the sale of common stock. If we license or sell any
of our technologies or drug candidates, then we will be foregoing a portion of
future revenues on potential products, if approved by the FDA. If we sell our
Class A common stock, then these issuances may dilute the value of our Class A
common stock and may adversely affect its market price. If we are unable to
successfully raise capital, we may need to curtail operations.

In order to maintain sufficient cash and investments for future operations, we
intend to raise additional capital in the next twelve months through various
alternatives, including licensing or sales of our technologies and drug
candidates and sale of shares of our Class A common stock.



| |  |  | If we raise capital through licensing or sales of one or more of
our technologies and drug candidates, then we may lose an opportunity
for product sales if a product is successfully developed, approved by
the FDA and marketed. If we license any of our technologies or drug
candidates, then the development of the product or technology will no
longer be in our control. A licensee might not ever reach any of the
milestones in a license agreement and we would not earn any additional
payments in such an event. Further, if we sell any of our technologies
or drug candidates, there can be no assurance that the sales price will
cover our investment in such technology or drug candidate.                                                                                                                                            
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | If we raise capital by issuing additional shares of Class A common
stock at a price per share less than the then-current market price per
share, then the value of the shares of Class A common stock outstanding
will be diluted or reduced. Further, even if we were to sell shares of
common stock at prices equal to or higher than the current market
price, the issuance of additional shares may depress the market price
of our common stock and dilute your voting rights in the Company. We
may not be able raise capital on terms that we find acceptable, if at all.
If we are unable to raise additional capital to fund future operations,
then we might have to reduce operations or defer or abandon one or more
of our clinical research programs. Any of these actions could be
expected to have an adverse effect on our stock price.

AVANIR and its licensees may not be successful in obtaining regulatory approval
of docosanol 10% cream immediately as an over-the-counter (OTC) product in
the rest of the world or in licensing, marketing and selling the product in
foreign countries.

AVANIR and its licensees face a wide variety of risks in foreign countries in
obtaining regulatory approval and in marketing and selling docosanol 10% cream,
including:



| |  |  | Regulatory approval requirements differ by country, and obtaining
approvals to market the drug in foreign countries may be difficult to
obtain, may require additional costly and time consuming clinical
trials, or may require prescription status first before obtaining
sufficient experience to warrant approval as an OTC product;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | Building product awareness of a new drug, whether prescription or
OTC, among customers or retail store decision makers may require a
substantial amount of product promotion, which does not guarantee
success;                                                                                                                         
|
| |  |  | Consumers may not perceive that docosanol 10% cream is superior to
existing and potentially new OTC products for oral herpes;                                                                                                                                                                                                           

28



---



##### Table of Contents





| |  |  | Acceptance of docosanol 10% cream in the OTC consumer market may
not be widespread; and                     
| | - |  | ------------------------------------------------------------------------------------------------------------
|
| |  |  | Potential price erosion could occur due to competitive products and
responses to our products introduction.

Developing and testing a drug candidate is a very expensive and time-consuming
process that may not ultimately lead to a marketable product.

We may spend millions of dollars in pre-clinical studies researching the
potential safety and efficacy of our drug candidates. If any such drug
candidate fails to demonstrate the desired safety and efficacy, we may abandon
the development of the compound, in which event we would not recover our
expenditures incurred to date for that compound. If a compound appears to be
safe and effective in pre-clinical studies, we may decide to proceed with human
clinical trials. The full complement of clinical trials required to obtain
regulatory approval for a new drug may involve several million dollars.
Because of the Companys limited financial resources, we may be required to
license the compound to a pharmaceutical company with greater financial
resources in order to complete development of the drug. There is no assurance
that we will be able to find a large pharmaceutical company interested in
licensing the drug or, if we do locate such a licensee, that the proposed
license terms will be acceptable to the Company. In the event that we are
unable to find a large pharmaceutical partner or licensee on acceptable terms,
we may be forced to abandon one or more of our drug candidates.

We expect our quarterly operating results to fluctuate significantly from
period-to-period for a number of reasons.

Future operating results will continue to be subject to significant quarterly
fluctuations based on a variety of factors, including:



| |  |  | Limited rights to future Abreva royalties In December 2002 we
sold to Drug Royalty USA the rights to a substantial portion of our
future royalty revenues from sales of Abreva by GlaxoSmithKline. We
will not receive any future royalty payments unless and until annual
Abreva sales exceed $62 million, at which time we will receive one-half
of the stated royalty rate on any excess sales. We expect that any
royalty payments on these excess sales, if any, would occur only once a
year, after the end of each calendar year.                                                                                                                                                                                                                                                                                                             
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | Concentration of significant customers, suppliers and industries
Milestone payments and royalties earned from a single licensee
(GlaxoSmithKline) accounted for approximately 95% and 99% of our fiscal
2002 and 2001 revenues, respectively. We have now received all of the
milestone payments from GlaxoSmithKline. With the sale of our Abreva
royalty rights to Drug Royalty USA, future royalty payments from
GlaxoSmithKline will come exclusively from our remaining 50% share of
Abreva royalties on contract sales in excess of $62 million a year.
Additionally, we purchase our raw materials from a sole foreign
supplier that has been approved for manufacture by the U.S. Food and
Drug Administration (FDA). Any disturbances or delays in the
manufacture of the raw materials could seriously and adversely affect
our business.

29



---



##### Table of Contents





| |  |  | Achievement of milestones under license agreements may be outside
our control Recognition of revenue under several of our license
agreements may depend solely on the efforts and performance of our
licensees in reaching milestones outside of our control. Such
milestones may include specific events, such as regulatory approval,
product launch, the passage of time, or reaching a sales threshold.                                                                                                                                                                                          
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | Acquisitions/alliances If, in the future, we acquire
technologies, products, or businesses, or we form alliances with
companies requiring technology investments or commitments, we will face
a number of risks to our business. The risks that we may encounter
include those associated with integrating operations, personnel, and
technologies acquired or licensed, and the potential for unknown
liabilities of the acquired business. Our business and operating
results on a quarterly basis could be adversely affected if any of our
acquisition or alliance activities are not successful.

Foreign sales of docosanol 10% cream and other potential products are subject
to various foreign trade risks.

Our license agreement with GlaxoSmithKline is for the United States and Canada
only. We also have exclusive license agreements for docosanol 10% cream for
Israel, South Korea, Italy and Egypt. We are holding discussions with other
potential licensees for marketing and selling docosanol 10% cream in other
countries not already licensed. However, we may not finalize any license or
distribution arrangements for other territories on a timely basis or on
favorable terms, if at all. Further, our foreign licensees expose us to
various foreign trade risks relating to development and marketing of docosanol
10% cream. We may arrange for contracts in the future for the manufacture,
marketing and distribution of docosanol 10% cream overseas by foreign
licensees, which will be substantially outside our control. Even if we are
able to obtain experienced licensees in foreign markets, specific risks that
could impact significantly our ability to deliver products abroad include:



| |  |  | difficulties in obtaining regulatory approval of docosanol 10% cream in foreign countries;                           
| | - |  | ---------------------------------------------------------------------------------------------------------------------
|
| |  |  | changes in the regulatory and competitive environments in foreign countries;                                         
|
| |  |  | changes in a specific countrys or regions political or economic conditions;                                        
|
| |  |  | difficulty in finding foreign partners with sufficient capital to
effectively launch, market and promote the product;
|
| |  |  | shipping delays;                                                                                                     
|
| |  |  | difficulties in managing operations across disparate geographic areas;                                               
|
| |  |  | fluctuations in foreign currency exchange rates;                                                                     
|
| |  |  | prices of competitive products;                                                                                      
|
| |  |  | difficulties associated with enforcing agreements through foreign legal systems;                                     
|
| |  |  | trade protection measures, including customs duties and export quotas; and                                           
|
| |  |  | foreign tax withholding laws.                                                                                        

30



---



##### Table of Contents



Our Xenerex antibody generation technology faces intense competition and rapid
technological change. If we fail to provide services that keep pace with new
technologies and gain market acceptance, our services and technologies could
become obsolete.

The biotechnology industry is highly competitive and subject to significant and
rapid technological change. We compete with several companies that offer
antibody generation services to other companies. These competitors have
specific expertise and technologies related to antibody development. Also,
they introduce new or modified technologies from time to time. These companies
include Abgenix, Inc., Medarex, GenPharm, Kirin Brewing Co., Genmab, Cambridge
Antibody Technology Group, Protein Design Labs, Dyax, and MorphoSys. Many of
these companies, either alone or together with their customers, have
substantially greater financial resources, larger research and development
staffs, and substantially greater experience than we do.

Our failure or inability to comply with government regulations regarding the
development, production, testing, manufacturing and marketing of our products
may adversely affect our operations.

Governmental authorities in the U.S., including the FDA, and other countries
highly regulate the development, production, testing, manufacturing and
marketing of pharmaceutical products. The clinical testing and regulatory
approval process can take a number of years and requires the expenditure of
substantial resources. Failure to obtain, or delays in obtaining, these
approvals will adversely affect our business operations, including our ability
to commence marketing of any proposed products. We may find it necessary to
use a significant portion of our financial resources for research and
development and the clinical trials necessary to obtain these approvals for our
proposed products. We will continue to incur costs of development without any
assurance that we will ever obtain regulatory approvals for any of our products
under development. Additionally, we cannot predict the extent to which adverse
governmental regulation might arise from future U.S. or foreign legislative or
administrative action. Moreover, we cannot predict with accuracy the effects
of any future changes in the regulatory approval process and in the domestic
health care system for which we develop our products. Future changes could
affect adversely the time frame required for regulatory review, our financial
resources, and the sale prices of our proposed products, if approved for sale.

Unsuccessful or lengthy research and development programs for proposed new
products could negatively affect our business.

The drug development process is lengthy and capital intensive. Our drug
development programs are exposed to all of the risks inherent in product
development based on innovative technologies, including unanticipated
development problems and the possible lack of funding or collaborative
partners. Any of a number of problems in the development process could result
in the abandonment or substantial change in the development of a specific
product. Our Phase III clinical trial of Neurodex for the treatment of
pseudobulbar affect in multiple sclerosis patients may experience setbacks or
failures for reasons we have not anticipated. Our Phase II open-label dose
escalation clinical trial of Neurodex for the treatment of neuropathic pain may
not show proof of concept. Our Phase I clinical trial of our lead compound for
treating allergy and asthma may not demonstrate the efficacy of, or have the
safety profile necessary for, a proposed product for human use. Unsuccessful
clinical trial results for our proposed products could affect materially and
adversely our future business operations and financial condition.

Business interruptions could adversely affect our business.

Our operations are vulnerable to interruption by fire, earthquake, power loss,
telecommunications failure, terrorist attacks and other events beyond our
control. For example, during 2001, California experienced shortages in
adequate supply of electricity, resulting in rolling blackouts, where certain
areas were not provided with any electricity for periods of up to two hours.
The immediate impact was a significant

31



---



##### Table of Contents



increase in power rates. Additionally, the loss of electrical power or
blackouts for any significant periods of time could harm our vendors and our
ability to conduct experiments and provide services. Further, we could lose
valuable data made to date in experiments currently underway. We have
attempted to mitigate the severity of power losses by installing emergency
power equipment, which we intend to use for those electrical needs that we
consider to be the most critical to operating our business. However, the
emergency power unit does not cover all of our electrical needs and, further,
it might not operate properly in the event of a power loss.

Our inability to attract and retain key management and scientific personnel
could negatively affect our business.

Our success depends on the performance of a small core staff of key management
and scientific employees with biotech experience. Given our small staff size
and programs currently under development, we depend substantially on our
ability to hire, train, retain and motivate high quality personnel, especially
our scientists and management team in this field. If we were to lose one or
more of our key scientists, then we would likely lose some portion of our
institutional knowledge and technical know-how, potentially causing a
substantial delay in one or more of our development programs until adequate
replacement personnel could be hired and trained.

Our future success also depends on our continuing ability to identify, hire,
train and retain highly qualified, technical, sales, marketing and customer
service personnel. We presently employ approximately 63 people. Further, we
expect to hire additional people over the next twelve months. Other than our
chief executive officer, our executives do not have employment agreements. We
do not have key person life insurance policies for any of our executives.
The industry in which we compete has a high level of employee mobility and
aggressive recruiting of skilled personnel. This type of environment creates
intense competition for qualified personnel, particularly in product research
and development, sales and marketing, and accounting and finance.

Our patents may be challenged and our pending patents may be denied. Either
result would seriously jeopardize our ability to compete in the intended
markets for our proposed products.

We rely substantially on the protection of our intellectual property through
our ownership or control of issued patents and patent applications. Patents
and patent applications owned or controlled by the Company are for
docosanol-related products and technologies, Xenerex technologies for
developing monoclonal antibodies, Neurodex, compounds capable of regulating
the target IgE in controlling symptoms of allergy and asthma, and compounds
capable of regulating the target MIF in the treatment of several inflammatory
diseases. Because of the competitive nature of the biopharmaceutical industry,
we cannot assure you that:



| |  |  | the claims in any pending patent applications will be
allowed or that patents will be granted;                                                                                       
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | present and future competitors will not develop similar
or superior technologies independently, duplicate our
technologies or design around the patented aspects of our
technologies;
|
| |  |  | our proposed technologies will not infringe other
patents or rights owned by others, including licenses that may
not be available to us;                                             
|
| |  |  | any of our issued patents will provide us with
significant competitive advantages; or                                                                                                

32



---



##### Table of Contents





| |  |  | challenges will not be instituted against the validity
or enforceability of any patent that we own or, if instituted,
that these challenges will not be successful.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Our inability to obtain or maintain patent protections for our products in
foreign markets may negatively affect our financial condition.

The process for the approval of patent applications in foreign countries may
differ significantly from the process in the U.S. These differences may delay
our plans to market and sell docosanol 10% cream and other products in the
international marketplace. Approval in one country does not indicate that
approval will be obtained in other countries. The patent authorities in each
country administer that countrys laws and regulations relating to patents
independently of the laws and regulations of any other country and we must seek
and obtain the patents separately. Our inability to obtain or maintain patent
protections for docosanol 10% cream and other products in foreign markets would
severely hamper our ability to generate international sales from our first
product and other products still under development.

If we do not protect our technical innovations, then our business may be
negatively affected.

We rely substantially on confidentiality agreements to protect our innovations.
We cannot assure you that secrecy obligations will be honored, or that others
will not develop independently similar or superior technology. Additionally,
if our consultants, key employees or other third parties apply technological
information independently developed by them or by others to our projects, then
disputes may arise as to the ownership rights of these innovations. It is
costly to litigate these disputes and an unfavorable result could adversely
affect our intellectual property portfolio as well as our business and
financial condition.

Developing new pharmaceutical products for human use involves product liability
risks, for which we currently have limited insurance coverage.

The testing, marketing, and sale of pharmaceutical products involves the risk
of product liability claims by consumers and other third parties. We maintain
product liability insurance coverage for our clinical trials in the amount of
$2 million per incident and $2 million in the aggregate. However, product
liability claims can be high in the pharmaceutical industry and our insurance
may not sufficiently cover our actual liabilities. If a suit against our
business or proposed products is successful, then the lack or insufficiency of
insurance coverage could affect materially and adversely our business and
financial condition. Furthermore, various distributors of pharmaceutical
products require minimum product liability insurance coverage before their
purchase or acceptance of products for distribution. Failure to satisfy these
insurance requirements could impede our ability to achieve broad distribution
of our proposed products.

We could incur significant liabilities as a result of material litigation.

In the ordinary course of business, we face various claims brought by third
parties, including claims relating to the safety or efficacy of our products.
Any of these claims could subject us to costly litigation and, while we
generally believe that we have adequate insurance to cover many different types
of liabilities, our insurance carriers may deny coverage or our policy limits
may be inadequate to fully satisfy any damage awards or settlements. If this
were to happen, the payment of any such awards could have a material adverse
effect on our operations and financial position. Additionally, any such
claims, whether or not successful, could damage our reputation and business.

Abreva faces competition from a number of existing and well-established
products and the companies that market their products.

33



---



##### Table of Contents






We have the opportunity to earn royalties on Abreva product wholesale sales if
sales exceed $62 million a year. Abreva competes with several other products
for oral-facial herpes currently on the market in the U.S., as well as other
products or potential products that are or may be under development or
undergoing FDA review. Most of our competitors, including such companies as
Bayer Corp. and Schering Plough, have substantial financial resources, research
and development facilities and manufacturing and marketing experience. Even
with Abreva being marketed by one of the worlds largest consumer healthcare
companies, GlaxoSmithKline, not all competitive responses and the impacts of
those responses can be foreseen.

The conversion of redeemable convertible preferred stock currently outstanding
will have a dilutive effect on our Class A common stock.

As of March 31, 2003, the Company had outstanding 50 shares of Series D
redeemable convertible preferred stock. The Series D stock can be converted at
any time into shares of our Class A common stock at a price equal to 86% of the
then-current market price. Based on our stock price as of March 31, 2003,
these shares would convert into 577,073 shares of Class A common stock. If our
stock price were to drop, the number of shares that may be acquired upon
conversion of the Series D stock would proportionately increase.

We do not intend to declare or pay cash dividends in the foreseeable future.

We do not intend to declare or pay cash dividends on our Class A or Class B
common stock in the foreseeable future. We expect to retain any earnings, if
and when achieved, to finance our business.

Item 3.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks related to changes in interest rates. Because
substantially all of our revenue, expense, and capital purchasing activities
are transacted in U.S. dollars, our exposure to foreign currency exchange rates
is immaterial. However, in the future we could face increasing exposure to
foreign currency exchange rates as we expand international distribution of
docosanol 10% cream. Until such time as we are faced with material amounts of
foreign currency exchange rate risks, we do not plan to use derivative
financial instruments, which can be used to hedge such risks. We will evaluate
the use of derivative financial instruments to hedge our exposures as the needs
and risks should arise.

Interest rate sensitivity

Our investment portfolio consists primarily of fixed income instruments with an
average duration of 1.7 years as of March 31, 2003 (2.3 years as of September
30, 2002). The primary objective of our investments in debt securities is to
preserve principal while achieving attractive yields, without significantly
increasing risk. We carry some investments that we intend to hold to maturity
and others that we classify as available-for-sale. These available-for-sale
securities are subject to interest rate risk. In general, we would expect that
the volatility of this portfolio would increase as its duration increases.




Item 4.    CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures designed to help ensure that
material information related to the Company, and its subsidiary, is made known
to our management and audit committee on a regular and current basis. We have
evaluated our controls and procedures within 90 days of the filing date of this
report and have concluded that our disclosure controls and procedures as of the
date of this filing are

34



---



##### Table of Contents



adequate to enable us to comply with our disclosure obligations. No
significant change to our internal controls was made during the period covered
by this report or subsequent to our evaluation.




PART II. OTHER INFORMATION

Items 1-3.     NOT APPLICABLE




Item 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Annual Meeting of Shareholders of AVANIR Pharmaceuticals was convened on
March 13, 2003, at 10:00 a.m. local time. There were issued and outstanding on
January 16, 2003, the record date, 58,294,533 shares of Class A common stock,
each share being entitled to one vote, and 13,500 shares of the Companys Class
B common stock, each share being entitled to five votes, constituting all of
the outstanding voting securities of the Company. There were present at the
meeting in person or by proxy, shareholders of the Company who were the holders
of 55,795,779 votes of the Companys common stock entitled to vote thereat,
constituting a quorum. The following votes were cast for each Class II
director nominee:

|                    |  |     |            |          |  |  |           | 
|------------------- |  | --- | ---------- | -------- |  |  | --------- | 
|                    |  | For |            | Withhold
|                    |  |     |            |         
|Stephen G. Austin   |  |     | 53,725,835 |          |  |  | 2,069,944 | 
|Charles A. Mathews  |  |     | 53,147,535 |          |  |  | 2,648,244 | 
|Harold F. Oberkfell |  |     | 53,726,535 |          |  |  | 2,069,244 | 

The proposal to ratify the selection of Deloitte & Touche LLP as the Companys
independent auditors for the fiscal year ending September 30, 2003, received
the following votes:

|           |  |         |           |         |  |  |         | 
|---------- |  | ------- | --------- | ------- |  |  | ------- | 
|For        |  | Against |           | Abstain
|           |  |         |           |        
|54,015,732 |  |         | 1,585,666 |         |  |  | 194,380 | 




Item 6.        EXHIBITS AND REPORTS ON FORM 8-K

| |  |     |  |  |       |  |  |                                                                                                   
| |  | --- |  |  | ----- |  |  | --------------------------------------------------------------------------------------------------
| |  | (a) |  |  | 10.1  |  |  | Amended and Restated 2000 Stock Option Plan                                                       
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 10.2  |  |  | Form of Restricted
Stock Grant Notice
for use with Amended and Restated 2000 Stock Option Plan    
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 10.3  |  |  | 2003 Equity Incentive Plan                                                                        
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 10.4  |  |  | Form of Non-Qualified Stock Option
Award Notice for use with 2003 Equity Incentive Plan           
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 10.5  |  |  | Form of Restricted Stock Grant Notice
for use with 2003 Equity Incentive Plan                     
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 10.6  |  |  | Form of Restricted
Stock Grant Notice (cash consideration) for use with 2003 Equity
Incentive Plan
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 15.0  |  |  | Letter on unaudited interim financial
information                                                 
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 99.1  |  |  | Certification pursuant to Section 906
of Sarbanes-Oxley Act of 2002                               
| |  |     |  |  |       |  |  |                                                                                                   
| |  |     |  |  | 99.2  |  |  | Certification pursuant to Section 906
of Sarbanes-Oxley Act of 2002                               
| |  |     |  |  |       |  |  |                                                                                                   
| |  | (b) |  |  | None. |  |  |                                                                                                   

35



---



##### Table of Contents






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

|                            |  |                                              |  |             
|--------------------------- |  | -------------------------------------------- |  | ------------
|Signature                   |  | Title                                        |  | Date        
|                            |  |                                              |  |             
|/s/Gerald J. Yakatan, Ph.D. |  | President and Chief                          |  | May 13, 2003
|                            |  | Executive Officer                            |  |             
|Gerald J. Yakatan, Ph.D.    |  | (Principal Executive Officer)                |  |             
|                            |  |                                              |  |             
|/s/Gregory P. Hanson        |  | Vice President, Finance and Chief            |  | May 13, 2003
|                            |  | Financial Officer                            |  |             
|Gregory P. Hanson           |  | (Principal Financial and Accounting Officer) |  |             

36



---



##### Table of Contents



CERTIFICATIONS

I, Gerald J. Yakatan, certify that:

1.       I have reviewed this quarterly report on Form 10-Q of Avanir
Pharmaceuticals;

2.       Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

3.       Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.       The registrants other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)  designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

b)  evaluated the effectiveness of the registrants disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the Evaluation Date); and

c)  presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

5.       The registrants other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrants auditors and the audit committee of
the registrants board of directors (or persons performing the equivalent
functions):

a)  all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrants ability to record,
process, summarize, and report financial data and have identified for the
registrants auditors any material weaknesses in internal controls; and

b)  any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal controls;
and

6.       The registrants other certifying officer and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

|                   |  |                                          
|------------------ |  | -----------------------------------------
|Date: May 13, 2003 |  | /s/ Gerald J. Yakatan                    
|                   |  |                                          
|                   |  | Gerald J. Yakatan
Chief Executive Officer

37



---



##### Table of Contents



I, Gregory P. Hanson, certify that:

1.       I have reviewed this quarterly report on Form 10-Q of Avanir
Pharmaceuticals;

2.       Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

3.       Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.       The registrants other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)  designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

b)  evaluated the effectiveness of the registrants disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the Evaluation Date); and

c)  presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

5.       The registrants other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrants auditors and the audit committee of
the registrants board of directors (or persons performing the equivalent
functions):

a)  all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrants ability to record,
process, summarize, and report financial data and have identified for the
registrants auditors any material weaknesses in internal controls; and

b)  any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal controls;
and

6.       The registrants other certifying officer and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

|                   |  |                                          
|------------------ |  | -----------------------------------------
|Date: May 13, 2003 |  | /s/ Gregory P. Hanson                    
|                   |  |                                          
|                   |  | Gregory P. Hanson
Chief Financial Officer

38



---



##### Table of Contents






EXHIBIT INDEX

|            |  |                                                                                                   
|----------- |  | --------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                       
|            |  |                                                                                                   
|10.1        |  | Amended and Restated 2000 Stock Option Plan                                                       
|            |  |                                                                                                   
|10.2        |  | Form of Restricted Stock Grant Notice for use with Amended and Restated
2000 Stock Option Plan    
|            |  |                                                                                                   
|10.3        |  | 2003 Equity Incentive Plan                                                                        
|            |  |                                                                                                   
|10.4        |  | Form of Non-Qualified Stock Option Award Notice for use with 2003 Equity
Incentive Plan           
|            |  |                                                                                                   
|10.5        |  | Form of Restricted Stock Grant Notice for use with 2003 Equity Incentive
Plan                     
|            |  |                                                                                                   
|10.6        |  | Form of Restricted Stock Grant Notice (cash consideration) for use
with 2003 Equity Incentive Plan
|            |  |                                                                                                   
|15.0        |  | Letter on unaudited interim financial information                                                 
|            |  |                                                                                                   
|99.1        |  | Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002                               
|            |  |                                                                                                   
|99.2        |  | Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002                               

39